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Abstract
Excessive hepatic glucose production is a hallmark of insulin resistance in type 2 diabetes. The cAMPresponsive transcription factor cAMP-responsive element binding protein (CREB), thought to be a key
activator of the hepatic gluconeogenic gene regulation program, has been suggested as therapeutic
target to reduce glucose output by the liver. Here, I test directly the requirement for hepatocytic CREB for
the maintenance of glucose homeostasis utilizing Cre-loxP for conditional, cell-type specific gene
ablation. Strikingly, I find no difference in fed and fasted glucose levels, or glucose, insulin, and glucagon
tolerance in mice fed normal chow or a high-fat diet in hepatocyte Creb-null mice compared to controls. In
addition, mRNA levels of liver specific genes, including several CREB target genes involved in
gluconeogenesis, were not affected by CREB deficiency in the liver. In conclusion, my data indicate that
CREB has no non-redundant functions in hepatic glucose metabolism, and is therefore not likely to be a
useful target for the development of anti-diabetic drugs.
Furthermore, lipolysis and thermogenesis are regulated by catecholamines signaling via β-adrenergic
receptors in adipose tissue and a role for the CREB in adipocyte function had been suggest by previous
studies. However the role of CREB in adipose tissue had never been evaluated in vivo. Here, I test directly
the requirement for adipocyte CREB for lipolysis and thermogenesis using the Cre-loxP system for
adipocyte-specific ablation of Creb in mice. Loss of adipocytic Creb lead to a moderate decrease in
fasting-induced lipolysis in adipose tissue. Strikingly, the adipocytic transcriptome was not globally
affected by ablation of Creb. In addition, cold temperature and cAMP signaling-induced thermogenesis
and white-to-beige adipocyte conversion were not changed in adipocyte specific Creb-null mice compared
to controls. In conclusion, my data indicate that CREB has no non-redundant functions in thermogenesis,
but contributes to the regulation of fasting-induced lipolysis. The underlying mechanism of reduced
fasting-induced lipolysis in adipocytic CREB-deficient mice will need to be explored further.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Pharmacology

First Advisor
Klaus H. Kaestner

Second Advisor
Mitchell A. Lazar

Keywords
Adipose Tissue, CREB, Liver, Metabolism, Transcriptional Regulation

Subject Categories
Genetics | Pharmacology | Physiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1342

	
  

THE ROLE OF CREB IN THE LIVER AND ADIPOSE TISSUE
Dolim Lee
A DISSERTATION
in
Pharmacology
Presented to the Faculties of the University of Pennsylvania
In Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2014

Supervisor of Dissertation

________________________
Klaus H. Kaestner, Ph.D.
Thomas and Evelyn Suor Butterworth Professor in Genetics
Graduate Group Chairperson

________________________
Julie A. Blendy, Ph.D., Professor of Pharmacology

Dissertation Committee
Mitchell A. Lazar, M.D., Ph.D. Sylvan H. Eisman Professor of Medicine (Chair)
Rexford A. Ahima, M.D., Ph.D. Professor of Medicine
Morris J. Birnbaum, M.D., Ph.D. Professor of Medicine
Julie A. Blendy, Ph.D., Professor of Pharmacology
	
  

	
  

DEDICATION
In loving memory of my mom,
Who always had answers to all my questions, for teaching me ‘joie de vivre’

To my dad,
A true family man, to whom I’ll be forever grateful in his unwavering love & support

To Yunna,
Sister, best friend, and my partner in crime, since 1987

To Gayeon
My baby sister for always bringing out the best in me

ii	
  

	
  

ACKNOWLEDGMENTS
First and foremost, I thank Dr. Klaus Kaestner for all his guidance and
encouragement. He has been a great mentor in both science and life. I am forever
indebted to him for supporting me through the most difficult time in my life. In addition,
I am grateful to all the members of my thesis committee for their guidance and support:
Dr. Rexford Ahima, Dr. Morris Birnbaum, Dr. Julie Blendy and Dr. Mitch Lazar, as well
as my prelim committee member Dr. Judy Meinkoth. Their expertise has been a
tremendous help in this thesis.
Furthermore, I thank all former and present members of the Kaestner lab for their
support and making this journey fun and interesting. In particular, I am thankful for Dr.
Lindsay McKenna who mentored me during my rotation, Dr. Sabina Lukovac for her
guidance and introducing me to the world of the small intestine, Dr. Soona Shin and Dr.
Karyn Sheaffer for their scientific advice, and Dr. Nuria Bramswig, Vasumathi
Kameswaran, Diana Bernstein, Ellen Elliott, and Rinho Kim for their friendship and
support. I also would like to thank Tia Bernard-Banks, Jonathan Schug, and members of
the Functional Genomics Core for technical support and contributions in regards to
crucial experiments in my thesis. I especially thank Dr. John Le Lay, a scientific mentor
and close friend, without whom this thesis work would never have existed. I am eternally
grateful for his scientific guidance and heated discussions and banters we shared in
regards to our beloved English football teams.
During my thesis research, I have been very fortunate to be surrounded by
colleagues at the Institute for Diabetes, Obesity and Metabolism. I want to thank Dr.
iii	
  

	
  

Patrick Seale and the members of his lab, members of the Lazar Lab, the Birnbaum Lab,
the Stoffers Lab, and the Mouse Phenotyping, Physiology and Metabolism Core for their
technical support and advice in designing key experiments and data interpretations in this
thesis. I am grateful to Dr. Jeff Raum for his scientific guidance, friendship, and for our
shared passion for Chelsea FC.
I give thanks to members of Pharmacology Graduate Group for their teachings,
guidance, and encouragement; in particular, Dr. Julie Blendy, Dr. Vladmir Muzykantov
and graduate group coordinator Sarah Squire. Furthermore, I thank all former and present
students of Pharmacology Graduate Group, and my classmates with whom I shared this
journey, for their friendship and support. I am especially grateful for Gabe Krigsfeld, Ed
Chen, Sonia Step, and Trisha Agrawal for standing by me through highs and lows, and
for all the great memories we shared that I will cherish forever.
Last but not least, I have been lucky to be surrounded by a group of amazing
friends both near and afar. I am especially thankful for Joohee Park, Syunghun Han and
Jinmin Lee. Because of them, I have always felt at home in Philadelphia. I am also
eternally grateful for Yujung Ko and Wooyoung Kang. Although we have each found our
own places in this world, you both have always been close to my heart.

iv	
  

	
  

ABSTRACT
THE ROLE OF CREB IN THE LIVER AND ADIPOSE
TISSUE
Dolim Lee
Klaus H. Kaestner

Excessive hepatic glucose production is a hallmark of insulin resistance in type 2
diabetes. The cAMP-responsive transcription factor cAMP-responsive element binding
protein (CREB), thought to be a key activator of the hepatic gluconeogenic gene
regulation program, has been suggested as therapeutic target to reduce glucose output by
the liver. Here, I test directly the requirement for hepatocytic CREB for the maintenance
of glucose homeostasis utilizing Cre-loxP for conditional, cell-type specific gene
ablation. Strikingly, I find no difference in fed and fasted glucose levels, or glucose,
insulin, and glucagon tolerance in mice fed normal chow or a high-fat diet in hepatocyte
Creb-null mice compared to controls. In addition, mRNA levels of liver specific genes,
including several CREB target genes involved in gluconeogenesis, were not affected by
CREB deficiency in the liver. In conclusion, my data indicate that CREB has no nonredundant functions in hepatic glucose metabolism, and is therefore not likely to be a
useful target for the development of anti-diabetic drugs.
Furthermore, lipolysis and thermogenesis are regulated by catecholamines
signaling via β-adrenergic receptors in adipose tissue and a role for the CREB in
v	
  

	
  

adipocyte function had been suggest by previous studies. However the role of CREB in
adipose tissue had never been evaluated in vivo. Here, I test directly the requirement for
adipocyte CREB for lipolysis and thermogenesis using the Cre-loxP system for
adipocyte-specific ablation of Creb in mice. Loss of adipocytic Creb lead to a moderate
decrease in fasting-induced lipolysis in adipose tissue. Strikingly, the adipocytic
transcriptome was not globally affected by ablation of Creb. In addition, cold temperature
and cAMP signaling-induced thermogenesis and white-to-beige adipocyte conversion
were not changed in adipocyte specific Creb-null mice compared to controls. In
conclusion, my data indicate that CREB has no non-redundant functions in
thermogenesis, but contributes to the regulation of fasting-induced lipolysis. The
underlying mechanism of reduced fasting-induced lipolysis in adipocytic CREB-deficient
mice will need to be explored further.
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CHAPTER 1: General Introduction
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1.1 Fuel Metabolism and Metabolic Organs

Keeping a tight balance between energy intake and expenditure is critical for all
living organisms. Disturbances in energy homeostasis lead to metabolic disorders such as
obesity, metabolic syndrome, and diabetes. Increase in the prevalence of obesity and
diabetes is a significant public health concern, and its patient population is projected to
grow faster than ever. In the U.S., currently more than two-thirds of adults are considered
obese or overweight (NIDDK), and one out of every 11 people have diabetes (CDC).
Mammals have evolved to efficiently convert food into energy that can be utilized by
individual cells, and to store excess energy for future use. In a healthy individual, each
digestive, endocrine, and exocrine organ serves a unique role in metabolism, and the
finely tuned feedback pathways between the organs ensures that blood glucose levels are
maintained near 4.5mM, despite constant fluctuations in dietary intake and energy
expenditure.

1.1.1

Small Intestine
During a meal, dietary nutrients are enzymatically digested and absorbed in the

small intestine. Some of digestive enzymes, such as disaccharidases, are secreted from
intestinal epithelial cells, while others, such as trypsin, elastase and lipases, are produced
in other organs, such as the pancreas, and transported to the small intestine. The liver also
plays an important role in the digestive process by producing bile, which solubilizes
2	
  

	
  

triglycerides in the diet. The lumen of the small intestine is lined with small finger-like
projections called villi, which increase the surface area available for absorption. Villi are
covered with a single layer of epithelial cells; most of which are absorptive cells, with
some goblet cells and enteroendocrine cells secreting mucus and gastrointestinal
hormones, respectively. At the base of each villi, there are glandular crypts that contain
replicating stem cells and paneth cells.
Dietary proteins are broken down into small peptides and amino acids by
proteolytic enzymes for absorption. Since only carbohydrate monomers can be absorbed
by the intestinal epithelium, complex carbohydrates are broken down into simple sugars,
such as glucose. Dietary lipids are degraded into fatty acids and glycerol by lipase, and
subsequently are absorbed by villi.

1.1.2

The Pancreas
The pancreas serves as both an endocrine and exocrine organ. The islets of

Langerhans are the endocrine part of the pancreas that secretes hormones, but make up
only 1-2% of pancreas mass. There are four types of cells in the islets of an adult
pancreas: α cells, β cells, δ cells, and polypeptide cells. During fasting, glucagon secreted
from α cells binds glucagon receptors on the surface of hepatocytes and promote hepatic
glucose production. In addition, glucagon increases triglyceride mobilization by
stimulating lipolysis in adipose tissue. Glucagon signaling also increases fatty acid
oxidation, allowing the use of lipid as an energy source, in all tissues except in the central
3	
  

	
  

nervous system. When blood glucose levels rise after a meal, β cells secrete insulin,
which promotes uptake and storage of glucose by the liver, skeletal muscles, and adipose
tissue. Also insulin increases fatty acid and triglyceride synthesis in the liver, and they
are packaged into very low-density lipoproteins and transported to adipose tissue. In the
adipose tissue very low-density lipoproteins are metabolized, and lipids are stored in
adipocytes. Opposing actions of glucagon and insulin keep blood glucose levels within a
constant range. Somatostatin secreted from δ cells is responsible for fine-tuning of
hormone secretion by α and β cells. Polypeptide cells secrete pancreatic polypeptides that
regulate pancreatic endocrine and exocrine secretions.
The exocrine pancreas makes up ≥90% of the total pancreas. It is composed of
acinar cells connected to small ducts that drain into the pancreatic ductal tree, which in
turn drain into the main pancreatic duct. Cells in the exocrine pancreas produce digestive
enzymes, enzyme precursors (zymogens), and bicarbonate, which make up pancreatic
juice. Pancreatic juice collected in pancreatic duct is released into the duodenum, the first
section of the small intestine.

1.1.3

The Liver
The liver is a central metabolic organ, and is responsible for processing and

distributing nutrients to extrahepatic tissues, including the brain. It also is important in
detoxification and synthesis of serum proteins. The liver is the first organ that receives
the nutrients absorbed by small intestine during a meal. Hepatocytes make up about 80%
4	
  

	
  

of the total liver mass, and are involved in carbohydrate metabolism, protein metabolism
and synthesis, and lipid processing and distribution.
The liver adapts to changes in blood glucose levels to maintain glucose
homeostasis as depicted in Figure 1.1. Upon receiving the insulin signal, excess glucose
received during a meal is converted into glycogen via glycogenesis, and stored for later
use. When blood glucose levels drop, i.e. during fasting, glucagon activates
glycogenolysis in hepatocytes, and glucose is released into bloodstream to be utilized by
other cells in the body. When the glycogen stores are depleted, the liver, and also
skeletal muscles, activates gluconeogenesis to produce glucose from non-carbohydrate
precursors, such as lactate, glycerol, alanine and glutamate, to meet glucose demand.
Diet-derived lipids are packaged into chylomicrons by small intestinal epithelial
cells and transported to the liver. The liver processes fatty acids into phospholipids and
triacylglycerol to form very low-density lipoproteins, to be transported to adipose tissue
for storage. Within hepatocytes, fatty acids can also serve as substrate for oxidation to
produce energy, cholesterol, and ketone bodies. Furthermore, when excess carbohydrate
is available, the liver converts carbohydrate into fat by de novo lipogenesis.
Amino acids taken up by the liver can serve as precursors for proteins, hormone
and nucleotide synthesis. During fasting, muscle protein is broken down and amino acids
are released into circulation, and then taken up by the liver. Some of these amino acids
are used as substrates to produce precursors for gluconeogenesis, while others are use in
ketogenesis.
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1.1.4

Adipose Tissue
White adipose tissue is mainly composed of white adipocytes whose primary role

is to store lipids. During a meal, glucose can be converted into fatty acids, and then to
triacylglycerides in adipose tissue for storage. Free fatty acids enter adipocytes, and with
glycerol, are assembled into triacylglycerides. When there is a demand for more energy,
epinephrine stimulates triacylglyceride hydrolysis and fatty acids are released into the
blood stream.
In rodents and human infants, although to a lesser extent in human adults, nonshivering thermogenesis occurs in specialized adipose tissue called ‘brown adipose
tissue’. Brown adipocytes have numerous mitochondria and smaller lipid droplets
compared to the large, single lipid droplet as in white adipocytes. Heat is generated via
uncoupling the mitochondrial respiratory chain through expression of high levels of
uncoupling proteins.

1.2 cAMP Response Element-Binding Protein (CREB)

1.2.1

cAMP Signaling Pathway
cAMP was the first “second messenger” discovered as a mediator of hormone

induced glucose production in the liver (Sutherland and Robison 1969; Montminy and
Bilezikjian 1987) . When ligands bind to cell-surface receptors that are coupled to
6	
  

	
  

heterotrimeric GTP binding proteins (G-proteins), the Gα subunit is activated and
dissociates from GβGγ. There are several different isoforms of the Gα subunit that can
interact with different effector molecules to carry out biological response to specific
ligand binding. For instance, upon epinephrine or glucagon signaling, activated Gαs can
stimulate adenylyl cyclase, an enzyme that converts ATP into cAMP.
Protein kinase A (PKA) is a cAMP-dependent protein kinase, whose activation is
regulated by intracellular cAMP levels. In the basal state, PKA is composed of two
regulatory subunits and two catalytic subunits. Binding of cAMP to regulatory subunits
causes release of catalytic subunits, allowing their translocation into the nucleus.
Activated catalytic subunits of PKA can regulate activity of downstream proteins by
phosphorylating Ser or Thr residues.

1.2.2

CREB mediates cAMP effects on Transcriptional Regulation
Nearly three decades ago, CREB was discovered as a nuclear protein that binds to

the cAMP response element (CRE), a conserved promoter element, located in the
somatostatin gene, and activates its expression in response to increased intracellular
cAMP levels (Montminy and Bilezikjian 1987). CREs can be either full palindromic
(TGACGTCA) or half-site (TGACG or CGTCA) sequences, and are often located in
proximal promoter regions (Zhang et al. 2005; Everett et al. 2013). CREB is a
ubiquitously expressed DNA binding transcription factor that forms a dimer, and
structurally belongs to the basic leucine zipper protein family (Hoeffler et al. 1988).
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There are other family members of CREB, which in addition to CREB are the activating
transcription factor 1 (ATF1) and cAMP- responsive element modulator (CREM), and
these two proteins can also mediate transcriptional response to cAMP signaling. CREB
family members share a conserved dimerization domain and kinase-inducible domain,
and some functional redundancy exists among them (Hummler et al. 1994). The G
protein-coupled receptor (GPCR) signaling pathway leading to activation of CREB is
depicted in Figure 1.2. Upon glucagon or epinephrine signaling, activated PKA
translocates into the nucleus, and phosphorylates CREB at Ser133 (Gonzalez and
Montminy 1989). This leads to activation of CREB, and promotes target gene expression
by recruitment of transcriptional co-activators, such as CREB-binding protein (CBP) and
p300, and RNA polymerase II complexes to promoters containing CREs. CBP and p300
have intrinsic histone acetyltransferase activity, which leads to loosening of chromatin
structure, thus increasing access for RNA polymerase, and results in increased expression
of downstream genes (Ogryzko et al. 1996).
More recently, the CREB-regulated transcription coactivator (CRTC), also known
as transducer of regulated CREB activity (TORC), family of cofactors was discovered
(Iourgenko et al. 2003). Although DNA binding by CREB does not depend on
recruitment of CRTC, presence of CRTC has been shown to enhance RNA polymerase II
interaction (Conkright et al. 2003). In the absence of a cAMP signal, cytoplasmic CRTC
is sequestered by 14-3-3 proteins, due to phosphorylation at Ser171 by Ser/Thr kinase 2
(SIK2) (Screaton et al. 2004). Elevation of cytoplasmic cAMP levels leads to inhibition
of SIK2 and dephosphorylation of CRTC, ultimately resulting in its dissociation from 148	
  

	
  

3-3 proteins and translocation into the nucleus for interaction with CREB (Screaton et al.
2004).

1.3 CREB in Glucose Homeostasis

1.3.1

Hepatocytic CREB as the Central Regulator of Gluconeogenesis
When blood glucose levels are low, glucagon secretion leads to inhibition of

glycogen producing glycogen synthase and activation of glycogen phosphorylase, a ratelimiting enzyme involved in breakdown of glycogen into glucose. During prolonged
fasting, starvation, or following intense exercise, glucose is also generated via
gluconeogenesis. Gluconeogenesis is essentially a reversal of glycolysis (Figure 1.3).
Three endergonic steps in glycolysis are catalyzed by three different key enzymes in
gluconeogenesis: phosphoenolpyruvate carboxykinase (PEPCK), fructose 1, 6bisphosphatase (FBPase), and glucose 6-phosphatase (G6Pase) (Figure 1.3).
Lactate is a major source of carbon atoms for gluconeogenesis. Lactate produced
by glycolysis in non-hepatic tissues is transported to the liver, and lactate dehydrogenase
converts lactate into pyruvate, the first designated substrate of gluconeogenesis (Figure
1.3). All amino acids, except leucine and lysine, can be converted into glucose. During
hypoglycemia, muscle proteins are broken down into amino acids and transported to the
liver. Some amino acids are catabolized into pyruvate, oxaloacetate or precursors of these.
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Glycerol from the breakdown of triacylglycerol in adipose also can be used for
gluconeogenesis.
Previous studies suggested CREB as the master regulator of gluconeogenesis in
the liver. CREs are located in proximal promoter regions of key gluconeogenic genes,
suggesting direct transcriptional regulation by CREB (Zhang et al. 2005; Everett et al.
2013). The model suggests that during short-term fasting, glucagon binds to GPCR on the
surface of hepatocytes, and activated CREB can induce transcription of gluconeogenic
genes, such as Pepck and G6pase (Montoliu et al. 1994; Herzig et al. 2001; Thiel et al.
2005) (Figure 1.4). CREB also increases expression of peroxisome proliferator-activated
receptor- γ (PPAR-γ) coactivator-1α (Pgc-1α), which can also interact with other coactivators at the transcription start site located in key gluconeogenic genes, further
activating expression of the gluconeogenic programing during prolonged fasting (Herzig
et al. 2001) (Figure 1.4).

1.3.2

CREB as a Potential Therapeutic Target for Type 2 Diabetes Mellitus
(T2DM)
Type 2 diabetes mellitus is a chronic metabolic disorder marked by

hyperglycemia, endocrine pancreatic dysfunction, and insulin resistance. T2DM accounts
for about 90% of all diagnosed cases of diabetes and is a major public health concern as
the fastest growing disease in the world. According to the CDC, there are currently 25.8
million Americans with diabetes, comprising 8.3% of the U.S. population. In 2010,
diabetes was the 7th leading cause of death in the U.S. (CDC). This is likely to be an
10	
  

	
  

underestimate, since failure to maintain glucose homeostasis contributes to other
detrimental complications such as cardiovascular disease, blindness, hepatic steatosis,
and kidney failure. Elevated hepatic gluconeogenesis, caused by increased glucagon
levels, decreased insulin secretion, and insulin resistance, is the major contributor to
fasting hyperglycemia in type 2 diabetic patients (Magnusson et al. 1992; Gastaldelli et al.
2000). There are three different types of drugs for T2DM: ones that help pancreatic
insulin secretion, ones enhance insulin sensitivity in peripheral tissue, and others that
limit excess glucose output from the liver. Although many advances have been made in
type 2 diabetes treatments, there are still safety and tolerability issues. With the expected
increase in the diabetic patient population and cost associated with the disease, there is a
strong need for development of a new class of drugs.
As the major mediator of cAMP effects on transcription of gluconeogenic genes
in the liver, CREB has been suggested as a potential drug target to reduce hyperglycemia
and hepatic insulin resistance in T2DM patients. To understand the effect of CREB
inhibition on glucose homeostasis, a dominant-negative inhibitor of CREB, A-CREB,
was utilized in many studies. A-CREB contains an acidic amphipathic protein sequence
that replaces the CREB basic region connected to the N-terminus of the dimerization
domain (Ahn et al. 1998). A-CREB forms a heterodimer with endogenous CREB protein
and prevents CREB from binding DNA. Expression of A-CREB via systemic injection of
adenovirus expressing A-CREB leads to a decrease in fasting glucose levels compared to
that of control, accompanied by a 4-fold decrease in expression levels of Pepck and
G6pase (Herzig et al. 2001). Also, overexpression of A-CREB was able to lower blood
11	
  

	
  

glucose levels of db/db mice to a normal range by lowering Pepck and Pgc1α mRNA
levels (Herzig et al. 2001). In a separate study, in order to induce tissue-specific reduction
of Creb expression, antisense oligonucleotide (ASO) was also utilized. Similar to the ACREB study, improvements in fasting glucose levels and lower gluconeogenic gene
expression levels were observed when hepatic and adipocytic Creb expression levels
were reduced by ASO in the rodent models of insulin resistance and obesity (Erion et al.
2009). Together, these results suggest CREB as a novel therapeutic target to lowering
blood glucose levels in T2DM patients by inhibiting excess gluconeogenesis in the liver.
However, despite both approaches leading to reduction of blood glucose levels,
they exhibited a contradicting hepatic lipid phenotype. Inhibition of CREB by A-CREB
lead to increased expression levels of lipogenic genes, such as Cd36, Fas, Acl, and Srebp,
with development of a fatty liver phenotype (Herzig et al. 2003). On the other hand,
Erion and colleagues found that CREB ASO alleviated fatty liver by reducing hepatic
triacylglycerol content and lowering lipogenic gene expression levels (Erion et al. 2009).
Fatty liver is commonly observed in type 2 diabetes patients, and although conditions
itself can be reversible; it can develop into detrimental conditions such as liver cirrhosis
and liver cancer, if left untreated. Thus this disagreement in the fatty liver phenotype
poses a serious threat in developing drugs against CREB.
Contradicting phenotypes from these studies could be explained in part by the
limitations of approaches taken. In the A-CREB study, expression of A-CREB was under
the control of the cytomegalovirus (CMV) promoter. Thus it is difficult to determine if
the lower blood glucose levels seen in A-CREB expressing mice were exclusively due to
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the inhibition of CREB activity in the liver. Furthermore, there is a possibility that some
observed phenotypes resulted from A-CREB interacting with other basic leucine zipper
proteins, including other CREB family members (Ahn et al. 1998). Similarly, CREBASO treatment affected Creb mRNA levels in both liver and white adipose tissue, which
makes it hard to determine if inhibition of hepatic, adipocytic CREB or combination of
both is required for the improvement of insulin sensitivity. In addition, there are potential
off-target effects by ASO. Therefore, there is a need for proper reevaluation of the current
understanding of CREB’s role in glucose homeostasis, to determine whether it could be
the next therapeutic target for T2DM.

1.4 Adipose Tissue Biology and Function

1.4.1

White and Brown Adipocytes
Despite their initial origin from pluripotent mesenchymal stem cells (MSCs),

white and brown adipocytes come from different precursor cells. Indeed, brown
adipocytes originate from myogenic factor 5 (myf5) and paired-box 7 (pax7) positive
precursors, which also give rise to myocytes (Hasty et al. 1993; Seale et al. 2008). The
differences between white and brown adipocytes are highlighted further by functions they
serve. As mentioned earlier, the main role of white adipose tissue (WAT) is to store
excess energy in a form of lipid droplets. Storage and utilization of lipids allows
adaptation to different energy needs throughout the day. Furthermore, WAT acts as an
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endocrine organ, producing and secreting protein hormones. These adipose-derived
hormones, adipokines, can influence inflammation (Bruun et al. 2001) and energy
metabolism (Hu et al. 1996; Halaas et al. 1997; Steppan et al. 2001). Unlike WAT, brown
adipose tissue (BAT) mainly functions in thermogenesis. White and brown adipocytes
have distinctive morphology that best serves their function. White adipocytes are mostly
made of a large single lipid droplet with its nucleus pushed to periphery. In contrast,
brown adipocytes contains multiple, small lipid droplets and numerous mitochondria,
which gives it a brown hue.

1.4.2

Lipolysis
Upon increased energy demand, triacylglycerol is catabolized to generate non-

esterified fatty acids (NEFAs) via lipolysis from adipocytes. Lipolysis can be induced by
several hormones; such as glucagon (Blecher et al. 1969; Exton et al. 1972), epinephrine
(Blecher et al. 1969; Exton et al. 1972), norepinephrine, growth hormone (Dietz and
Schwartz 1991), adrenocorticotropic hormone (Blecher et al. 1969), and thyroidstimulating hormone (Goodman and Bray 1966; Gagnon et al. 2010). Binding of these
hormones to GPCRs leads to activation of the cAMP signaling pathway, and activation of
lipolytic enzymes. During lipolysis, triacylglycerol is initially hydrolyzed into
diacylglycerols and NEFAs by adipose triglyceride lipase (ATGL) (Zimmermann et al.
2004). Hormone-sensitive lipase (HSL) is the rate-limiting enzyme of diacylglycerol
hydrolysis that produces monoacylglycerol and NEFAs (Osuga et al. 2000; Haemmerle et
al. 2002). HSL is also capable of hydrolyzing other acylesters like triacylglycerol,
14	
  

	
  

monoacylglycerol, cholesteryl esters, and retinyl esters. As the name suggests, lipolytic
hormone signaling leads to phosphorylation of HSL by PKA, and activated HSL
translocates to the lipid droplet (Clifford et al. 2000). Lastly, monoglyceride lipase (MGL)
breaks down monoacylglycerol into glycerol and NEFAs (Karlsson et al. 1997). NEFAs
and glycerol produced during lipolysis are delivered to peripheral tissues for energy
production.

1.4.3

Thermogenesis and Energy Expenditure
BAT is a major site of non-shivering thermogenesis in many mammals.

Uncoupling protein-1 (UCP1) in the inner membrane of brown adipocyte mitochondria
decreases the proton gradient, and uncouples oxidative phosphorylation, leading to heat
generation. Thermogenesis is regulated mainly by the sympathetic nervous system
through norepinephrine signaling (Landsberg et al. 1984). Β3-adrenergic receptors are
mainly found in white and brown adipose tissue and regulate lipolysis and thermogenesis.
Norepinephrine binds Β3-adrenergic receptors on brown adipocytes, and the cAMP
signaling is induced downstream (Cannon et al. 1996). A rise in intracellular levels
activates PKA, which phosphorylates a series of target enzymes that stimulates
expression and activation of UCP1. PGC1α is coactivator of adaptive thermogenesis, and
enhance transcription of Ucp1 (Puigserver et al. 1998; Wu et al. 1999). Also, lipolysis is
induced by activation of HSL and deactivation of perillipin that releases glycerol and free
fatty acids from lipid droplets. Fatty acids serve as both activators of UCP1 and
substrates for oxidative phosphorylation (Figure 1.5).
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It has been demonstrated that thermogenesis can be also activated by food intake
as well as cold exposure, linking energy expenditure and thermogenesis (Rothwell and
Stock 1979; Rothwell et al. 1982). Thus, there is interest in BAT as a potential antiobesity target, since thermogenesis burns and ‘wastes’ large amounts of lipids and
glucose (Lockie et al. 2013; Mund and Frishman 2013; Chechi et al. 2014). Defective
thermogenesis is shown to be associated with obesity in rodent models of genetic obesity
and T2DM, due to deficits in energy expenditure (Trayhurn and James 1978; Trayhurn
1979; Hogan and Himms-Hagen 1980; Trayhurn and Fuller 1980). In humans, presence
of BAT in adults has only been recognized recently (Hany et al. 2002; Yeung et al. 2003).
Some studies have indicated an inverse correlation between body mass index and BAT
activity (Cypess et al. 2009; Saito et al. 2009; van Marken Lichtenbelt et al. 2009).
Therefore BAT activity can potentially contribute to energy expenditure in adult humans.

1.4.4

Beige Adipocytes
More recently, another class of adipocytes called beige (brite) adipocyte was

discovered. Beige adipocytes are subset of traditional white adipocytes transformed to
express UCP1 after cold stimulation or chronic treatment with agonists that elevate
intracellular cAMP levels (Young et al. 1984; Cousin et al. 1992; Ghorbani et al. 1997;
Ghorbani and Himms-Hagen 1997; Petrovic et al. 2010). In rodents, beige adipocytes
mostly arise from the inguinal WAT (Vitali et al. 2012). Although these beige adipocytes
are similar to white adipocytes in the basal state with low expression of thermogenic gene
program, cAMP stimulation increases expression of thermogenic genes including Ucp1 at
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levels similar to those in brown adipocytes, suggesting thermogenic ability (Wu et al.
2012). Molecular characteristics of human brown adipocytes are similar to that of murine
beige adipocytes rather than brown adipocytes (Wu et al. 2006). Thus simulants that
induce ‘browning’ of white adipose tissue may be useful in treating obesity and diabetes
in humans.

1.4.5

CREB in Adipose Tissue
In previous study, obese mice expressing a dominant-negative CREB in

adipocytes displayed improved insulin sensitivity and were protected from adipose tissue
inflammation (Qi et al. 2009). In addition, CREB-regulated transcription coactivator 3
(CRTC3) was shown to promote obesity by attenuating β-adrenergic receptor signaling in
adipose tissue (Song et al. 2010). These studies suggest that adipocytic CREB plays an
important role in energy homeostasis.
In brown adipocytes, CREB can be activated by both classical β3- adrenergic/PKA
and α1-adrenergic/protein kinase C pathway (Chaudhry and Granneman 1999; Thonberg
et al. 2002). Thermogenesis is under positive adrenergic control and it is possible for
CREB to mediate expression of key genes involved in thermogenesis, including Ucp1.
Proximal promoter regions of the mouse Ucp1 gene contain half-CREs along with other
cis-regulatory elements such as peroxisome proliferator-activated receptor response
elements (PPREs) and thyroid response elements (TREs) (Kozak et al. 1994; Rim and
Kozak 2002). Cold-stimulated UCP1 levels in beige adipocytes were higher in the A/J
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strain of mice compared to that of the obesity-prone C57BL/6J strain, and coincided with
higher activation of CREB (Xue et al. 2005). Furthermore, CREB was found to form a
heterodimer with CCAAT/enhancer-binding protein beta (C/EBPβ), and regulate cAMPinduced expression of Pgc1α in adipocytes which also plays a role in cold-induced
thermogenesis by regulating Ucp1 expression (Karamanlidis et al. 2007; Karamitri et al.
2009). Despite these studies implying potential regulation of thermogenesis by CREB,
the role of CREB in adipocytes has never been investigated directly.

1.5 Hypothesis and Objectives
The liver is the central regulator of glucose homeostasis. It quickly adapts to
changes in energy demand of the body, storing excess glucose during feeding and
producing glucose via glycogenolysis and gluconeogenesis during fasting and intense
physical activity. In T2DM patients, increased hepatic glucose output is the major cause
of hyperglycemia. CREB has been established as the central regulator of gluconeogenesis
(Herzig et al. 2001; Erion et al. 2009), implying it as an attractive therapeutic target to
reduce blood glucose levels. Based on previous studies, loss of hepatic CREB is expected
to reduce circulating glucose levels due to decreased gluconeogenesis. To address this
hypothesis, in Chapter 3, I evaluate glucose homeostasis and insulin sensitivity in mice
with hepatocytic ablation of CREB, and reveal that CREB has no non-redundant function
in hepatic regulation of glucose homeostasis, which disproves conventional
understanding of CREB’s role as the master regulator gluconeogenesis (Herzig et al.
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2001; Erion et al. 2009). This work provides definitive understanding of the role of
CREB in the liver, and helps determining whether CREB is a useful therapeutic target.
Adipose tissue is a dynamic organ actively involved in regulation of energy
expenditure. Lipolysis and thermogenesis are under the control of adrenergic signaling
coupled to the cAMP-signaling pathway. As one of the major effectors of cAMP on
transcriptional regulation, I hypothesize that CREB is involved in activation of
thermogenesis and white-to-beige adipocyte transformation via regulation of Ucp1
expression. In Chapter 4, I investigate the role of CREB in adipose tissue in regulation of
thermogenesis and beige adipocyte formation. This work investigates CREB in
thermogenesis, which has been stipulated but never tested before.
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Figure 1.1: Hepatic Glucose Metabolism
The liver responds to glucagon and insulin signaling and adapts to different blood
glucose levels. Excess glucose is stored in the liver in the form of glycogen. When
needed, glucose can be released from glycogen stores or produced from non-carbohydrate
precursor.
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Figure 1.2: Activation of CREB via cAMP signaling
In a basal state, inactive CREB is bound to CREs near the transcription start site of target
genes. Binding of agonist to GPCRs lead to increase in intracellular cAMP levels.
cAMPs can activate PKA, and its catalytic subunits translocate to the nucleus. CREB is
activated when PKA phosphorylates Ser133 on CREB, inducing transcription.
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Figure 1.3: Glycolysis and Gluconeogenesis
Gluconeogenesis is essentially a reversal of glycolysis. Three key gluconeogenic
enzymes that bypass endergonic reactions are highlighted with stars.
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Figure 1.4: Model of proposed transcriptional regulation of gluconeogenic genes by
CREB
from (Altarejos and Montminy 2011). During short-term fasting, CREB stimulates
transcription of Pgc1α and members of the nuclear receptor subfamily 4 group A (Nr4a)
family of orphan nuclear receptors, in addition to key gluconeogenic genes. During
prolonged fasting, PGC1α and NR4A1 can further induce gluconeogenesis by interacting
with other transcription factors or directly binding to cis-regulatory regions of
gluconeogenic genes.
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Figure 1.5: Thermogenesis
from (Klaus 2001). Norepinephrine activates cAMP signaling via β-adrenergic receptors.
PKA activates HSL via phosphorylation, and triacylglycerols are hydrolyzed to produce
glycerol and fatty acids. Fatty acids are substrates for oxidative phosphorylation. In
addition, fatty acids can also activate UCP1, which mediates heat generation by
uncoupling respiratory chain.
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CHAPTER 2: Materials and Methods
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Animals
For the derivation of CrebloxP mice, a 12kb DNA fragment containing exon 11 of
the Creb gene was retrieved from C57BL/6J mouse BAC clone RP23-31C24 via bacterial
recombination. One loxP site was inserted upstream of exon 11, while a pair of loxP sites
flanking a neomycin selection cassette was placed downstream of exon 11. The
linearized targeting vector was electroporated into B6 ES cells (Chemicon) and clones
surviving selection were screened for homologous recombination by Southern blot
analysis. Targeted clones were injected into C57BL/6J-derived blastocysts that were then
transferred to pseudo-pregnant females. Male offspring were mated to C57BL/6J females
and ES cell-derived offspring were identified by PCR-based genotyping. Mice harboring
the targeted insertion of the three loxP sites in the Creb locus were crossed to the EIIaCre line to achieve mosaic germ line deletion of loxP-flanked sequences. The derivation
of the CrebloxP was performed by Dr. John Le Lay.
For liver-specific deletion of the CrebloxP alleles, CrebloxP/loxP mice were
anaesthetized with isoflurane and injected with adeno-associated virus expressing Crerecombinase under the control of the thyroxine-binding globulin (Tbg) promoter (AAVCre). Homozygous mice injected with virus expressing GFP (AAV-GFP) were used as
controls. Adeno-associated virus are generated by the Penn Vector Core. The expression
of GFP or Cre in wild-type livers using this viral delivery system did not result in any
detectable changes in carbohydrate or lipid metabolism. Normal mouse-chow diet (5015;
Purina Mills) fed mice were injected with adeno-associated virus at 8 to 10 weeks of age.
A cohort of mice was started on high fat diet (60% kcal from fat; D12492; Research
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Diets) upon weaning. Mice fed a high fat diet were injected with adeno-associated virus
at 12 to 14 weeks of age. All mice are given virus injection of 2 x 1011 genomic copies
per mouse. Experiments were performed two weeks after virus injection to ensure
complete deletion and decay of residual proteins.
For adipocyte-specific deletion of CrebloxP alleles, CrebloxP/loxP mice were crossed
with Adipoq-Cre mice (Eguchi et al. 2011; Lee et al. 2013). CrebloxP/loxP mice were used
as controls. Mice were analyzed between 3 to 5 months of age.
All the animal care and use procedures followed the guidelines of the Institutional
Animal Care and Use Committee of the University of Pennsylvania.

Whole Cell Lysate Preparation and Western Blot Analysis
Tissue fragments were homogenized by hand in 200µL of RIPA buffer containing
20mmol/l Tris (pH 8.0), 5mmol/l EDTA, 150mmol/l NaCl, 1% TritonX-100, 1% SDS
and 0.5% deoxycholic acid, supplemented with a protease inhibitor cocktail (Roche), then
sonicated using a Bioruptor (Diagenode). Whole-cell lysates were centrifuged at
maximum speed for 15 min to sediment cellular debris, and the supernatant was
collected. Protein concentrations were measured via Bradford assay using the “Protein
Assay Reagent” (Bio-Rad).
Approximately 50µg of whole-cell lysates were separated by SDS-PAGE and
transferred to nitrocellulose membranes (Invitrogen). Membranes were blocked in buffer
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containing 5% milk and 0.1% Tween-20 in 1X PBS (milk-PBST) for 30 min, then
incubated overnight at 4°C with primary antibodies diluted in milk-PBST. After washing,
membranes were incubated with HRP-conjugated secondary antibodies in milk-PBST for
1hr at room temperature. Proteins were visualized using the ECL-prime Western Blotting
Detection System (Amersham GE).

Immunohistochemistry
Following tissue harvest, tissues were rinsed in phosphate-buffered saline (PBS)
and fixed in 4% paraformaldehyde overnight, then embedded in paraffin, or
cryoprotected in 30% sucrose/PBS overnight at 4°C and frozen embedded in OCT and
frozen. Tissue blocks were sectioned by the CHOP Pathology Core. Sections were
blocked with normal donkey serum in PBS and incubated with primary antibody at 4°C
overnight. Fluorophore-conjugated secondary antibodies were applied for 2 h at room
temperature, and nuclei were stained with DAPI. Hepatocytes were counted using an
Olympus BG-2 microscope connected to a video camera with a color monitor.

Antibodies
CREB antibody was purchased from Cell Signaling, USA (#9197). HNF4α
antibody was purchased from R&D Systems (2ZH1415H). Cyclophilin B was obtained
from Pierce (PA1-027A). Donkey-anti-rabbit IgG and donkey anti-mouse IgG were
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obtained from Amersham GE. Cy3-conjucated donkey anti-rabbit secondary antibody
and Cy5-conjugated donkey anti-mouse secondary antibody were from Jackson
ImmunoResearch Laboratories)

Glucose Tolerance Test, Insulin Tolerance Test, and Glucagon Stimulation Test
Glucose tolerance tests were performed on mice fasted for 16hrs; while insulin
tolerance test and glucagon stimulation test were performed on mice fasted for 3hrs.
Animals on regular chow were administered 2g/kg body weight glucose, while those on
the high fat diet were administered 1.5g/kg body weight glucose to prevent glucose
excursions outside the measurable range. Animals were administered 0.75U/kg body
weight human insulin (Novo Nordisk), or 16µg/kg body weight glucagon by intraperitoneal injection. Blood was sampled from the tail vein at multiple time points and
glucose levels were measured with a Breeze 2 Glucose Meter (Bayer).

Metabolic Cage Study with Norepinephrine and CL-316,243 Treatment
During comprehensive metabolic monitoring, animals were kept at 30°C.
75mg/kg body weight nembutol was administered for anesthesia. Once mice are sedated,
animals were given subcutaneous injection of 1mg/kg body weight norepinephrine
(Sigma Aldrich), or CL-316,243 (Sigma Aldrich). O2 consumption and CO2 production
were measured, and body heat produced was calculated by indirect calorimetry.
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Metabolic cage experiments were performed by the Mouse Phenotyping, Physiology and
Metabolism Core.

CL-316,243 Treatment
Animals were moved to 30°C one-week prior to the start of injection, and kept at
30°C until tissue harvest. Once acclimated to thermoneutrality, animals were injected
1mg/kg body weight CL-316,243 (Sigma Aldrich) subcutaneously, once a day for 3 days,
and their tissues were collected 24hrs after the last injection.

Hepatic Lipids, Plasma Lipid and Plasma Adiponectin Measurement
Liver fragments were homogenized in PBS. Blood was collected from the tail
vein after 16hr fasting and 2hr refeeding with lithium-heparin coated microvette
(Sarstedt). Blood samples were centrifuged for 5 min at 4°C to separate plasma. Hepatic
triacylglycerol and cholesterol levels were measured via colorimetric assay with Infinity
triglyceride reagents (Thermo Scientific) and Infinity cholesterol reagents (Thermo
Scientific). Plasma NEFA, triacylglycerol and β-hydroxybutyrate were measured via
colorimetric assay with HR Series NEFA-HR (2) kit (Wako Diagnostics), Infinity
triglyceride reagents (Thermo Scientific) and β-hydroxybutyrate liquicolor kit (Stanbio),
respectively. Plasma adiponectin levels were measured using an adiponectin ELISA kit
(Linco).
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RNA Isolation and Quantitative RT-PCR Analysis
Total cellular RNA was extracted from tissue fragments using TRIzol (Invitrogen)
and the RNeasy Kit (Qiagen), according to the manufacturer’s protocol. Approximately 1
µg of total RNA was reverse transcribed using oligo(dT) and Superscript II Reverse
Transcriptase (Invitrogen). The resulting cDNA samples were employed as template for
quantitative RT-PCR experiments performed with Brilliant III Ultra-Fast SYBR QPCR
Mastermix (Agilent) and the SYBR Green (with dissociation curve) program on the
Mx300 Multiplex Quantitative PCR System (Stratagene). Reactions were performed in
triplicate and normalized relative to the ROX reference dye. Median cycle threshold
values (Ct) were determined and used for analyses. Expression levels were normalized to
those of hypoxanthine-guanine phosphoribosyltransferase (HPRT) as the internal control.
Primers are listed in Table 2.1.

mRNA Expression Profiling via Microarray
RNA isolated from the liver and adipose tissue of overnight-fasted four control
and four Creb mutant mice, were amplified and labeled using Low-Input Quick Amp
labeling kits (Agilent). Labeled samples were hybridized overnight to a 4  ×  44 whole
mouse genome array (Agilent). Arrays were washed and then scanned with the G2565B
DNA microarray scanner (Agilent). Genes displaying a fold-change over 1.5-fold
between mutants and controls and a false discovery rate <10%, calculated using
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significance analysis of microarray analysis (Tusher et al. 2001), were determined as
significantly changed. Data analysis was prformed by the Functional Genomics Core.

Primer Sequence (‘5→3’)
mRNA

Fwd

Rev

Cidea

TGCTCTTCTGTATCGCCCAGT

GCCGTGTTAAGGAATCTGCTG

Creb

AAGCAGCACGGAAGAGAGAG

TTTTCAAGCACTGCCACTCTG

Crem

TGCCTGGTATTCCCAAGATT

TTGTATTGCCCCGTGCTAGT

Dio2

CAGTGTGGTGCACGTCTCCAATC

TGAACCAAAGTTGACCACCAG

Fbpase

GCATCGCACAGCTCTATGGT

ACAGGTAGCGTAGGACGACT

G6pase

GCAAGGAGACCCAGGATTCTT

TGGGCTAGGGAAAGGAGTCAT

Pepck

TGCCCAAGGCAACTTAAGGG

CAGTAAACACCCCCATCGCT

Pgc1α

GGTCGAACGAAACTGACTTCG

GCAGGGTCAAAATCGTCTGAG

Pparα

GCGTACGGCAATGGCTTTAT

GAACGGCTTCCTCAGGTTCTT

Prdm16

CAGCACGGTGAAGCCATTC

GCGTGCATCCGCTTGTG

Ucp1

ACTGCCACACCTCCAGTCATT

CTTTGCCTCACTCAGGATTGG

Table 2.1: List of quantitative RT-PCR primers
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CHAPTER 3: The Transcription Factor CREB has No NonRedundant Function in Hepatic Glucose Metabolism
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As Published in Diabetologia, June 2014
3.1 Abstract
Excessive hepatic glucose production is a hallmark of insulin resistance in type 2
diabetes. The cAMP-responsive transcription factor cAMP-responsive element binding
protein (CREB), thought to be a key activator of the hepatic gluconeogenic gene
regulation program, has been suggested as therapeutic target to reduce glucose output by
the liver. Here, I test directly the requirement for hepatocytic CREB for the maintenance
of glucose homeostasis. I derived mice with a Creb loxP allele for conditional, cell-type
specific gene ablation. Hepatocyte-specific deletion of Creb was induced by injecting
CrebloxP/loxP mice with Cre-expressing adeno-associated virus (AAV-Cre). Strikingly, I
find no difference in fed and fasted glucose levels, or glucose, insulin, and glucagon
tolerance in mice fed normal chow or a high-fat diet. In addition, mRNA levels of liver
specific genes, including several CREB target genes involved in gluconeogenesis, were
not affected by CREB deficiency in the liver. In conclusion, my data indicate that CREB
has no non-redundant functions in hepatic glucose metabolism, and is therefore not likely
to be a useful target for the development of anti-diabetic drugs.
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3.2 Introduction
The cAMP response element binding protein (CREB) is a ubiquitous transcription
factor that belongs to the basic leucine zipper class (Dwarki et al. 1990). CREB
contributes to the regulation of genes containing cAMP-responsive elements (CREs) in
response to changes in cellular cAMP levels. In the liver, key gluconeogenic genes
contain CREs in their proximal promoters (Zhang et al. 2005; Everett et al. 2013).
Previous studies suggested that CREB is required for the regulation of gluconeogenesis
during fasting via recruitment of transcriptional co-activators to cis-regulatory elements
of relevant genes upon glucagon signaling (Herzig et al. 2001; Zhou et al. 2004; Koo et
al. 2005; Le Lay et al. 2009).
Elevated hepatic gluconeogenesis, caused by increased glucagon levels,
insufficient insulin secretion, and insulin resistance, is the major contributor of fasting
hyperglycemia in type 2 diabetic patients (DeFronzo et al. 1989; Magnusson et al. 1992;
Gastaldelli et al. 2000). Despite previous reports implicating inhibition of CREB as a
means to reduce blood glucose in the liver, the specific requirement for CREB in hepatic
glucose metabolism has never been addressed, and prior studies on CREB function
reported conflicting results (Herzig et al. 2001; Herzig et al. 2003; Erion et al. 2009).
Specifically, there was a significant increase in hepatic triacylglycerol levels in the livers
of mice expressing acidic-CREB (A-CREB), a dominant-negative inhibitor of CREB
function, while mice treated with antisense oligonucleotides (ASO) were protected from
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hepatic steatosis (Herzig et al. 2003; Erion et al. 2009), suggestive of non-specific effects
of one or both approaches.
Therefore, to assess the specific role of CREB in the liver in vivo, I employed a
conditional gene ablation approach. By deleting Creb in adult hepatocytes using Cre
recombinase expressing adeno-associated virus in CrebloxP/loxP mice, I demonstrate that
CREB is not required for the regulation of hepatic glucose metabolism.

3.3 Results

3.3.1

Conditional ablation of Creb in hepatocytes
To assess hepatic CREB function in vivo, a CrebloxP conditional null allele was

derived via homologous recombination in mouse embryonic stem cells. The targeting
strategy used to construct this mutant allele is shown in Figure 3.1. loxP sites were
positioned upstream and downstream of exon 11 to result in deletion of this critical exon
encoding the DNA binding domain upon exposure to Cre recombinase. In order to obtain
mice with hepatocyte-specific deletion of Creb, I used an AAV serotype that
preferentially infects hepatocytes, and controlled expression of Cre recombinase further
by placing it under the control of the hepatocyte-specific thyroxine-binding globulin
(Tbg)-promoter (Figure 3.1). Quantitative RT-PCR indicated an 80% decrease in Creb
mRNA expression in whole liver, consistent with the contribution of hepatocytes to liver
mass (Figure 3.2a). Western blotting confirmed the effective reduction of CREB protein
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levels in the livers of CrebL/L, AAV-Cre mice, with the remaining CREB protein in
mutant animals stemming from cells other than hepatocytes (Figure 3.2b). In order to
confirm complete ablation of Creb specifically in hepatocytes, dual labelimmunofluorescence staining with antibodies against the hepatocyte-specific marker
(HNF4α) and CREB protein (Figure 3.2c, d) were performed. CREB protein was absent
from all hepatocytes two weeks post AAV-Cre injection (Figure 3.2e), while Creb
expression in cholangiocytes and non-paranchymal cells such as stellate and Kupffer
cells was maintained (Figure 3.2e), indicating 100% efficiency and specificity of the
AAV-Cre system.

3.3.2

No changes in blood glucose homeostasis in the absence of hepatic Creb
Since previous studies had suggested that CREB serves as the master regulator of

gluconeogenesis via transcriptional regulation, I first examined blood glucose levels in
CrebL/L; AAV-Cre mice and control CrebL/L; AAV-GFP mice after fasting and during
refeeding. Surprisingly, there was no difference between blood glucose levels of control
and Creb-deficient mice (Figure 3.3a). To further analyze the effect of Creb ablation on
glucose homeostasis, glucose and insulin tolerance tests were performed. In agreement
with results from fasted and refed glucose measurements, no significant differences
between control and Creb-null mice were observed in these assays (Figure 3.3b, e). In
addition, insulin levels during glucose tolerance tests were indistinguishable between the
two groups (Figure 3.3c). To assess the possibility that CREB’s role in regulating
gluconeogenesis might be masked by glycogen breakdown during a short-term fast, blood
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glucose levels were measured during a 72 hour-long starvation period, when hepatic
gluconeogenesis becomes essential. Strikingly, even during the prolonged fast,
hepatocyte-specific Creb ablation had no effect on blood glucose levels (Figure 3.3d).
Thus, CREB is not required in hepatocytes to maintain blood glucose levels.

3.3.3

Ablation of hepatic Creb does not improve insulin sensitivity
It has been reported that inhibition of CREB activity in the liver leads to

improvement of hepatic insulin sensitivity in various insulin-resistant rodent models,
suggesting that CREB might be an attractive therapeutic target for the treatment of type 2
diabetic patients (Herzig et al. 2001; Erion et al. 2009). To evaluate this possibility, I
assessed the effects of hepatocyte-specific deletion of Creb on hepatic and peripheral
insulin sensitivity in the high-fat diet-feeding model. Unlike previous reports employing
different modes of non-specific CREB inhibition (see discussion), I did not observe
decreases in blood glucose levels after fasting and during refeeding in Creb-deficient
mice that had been on a high-fat diet for 10 weeks relative to control mice (Figure 3.4a).
Because of animals developing insulin resistance after high-fat feeding, I used a smaller
glucose amount for the studies of high-fat diet fed mice to prevent glucose excursions
outside the measurable range. There was no improvement in glucose or insulin tolerance
in high-fat diet fed Creb mutant mice compared to controls (Figure 3.4b, c). To
investigate the effects of hepatocytic Creb ablation in mediating glucagon signaling and
activation of the gluconeogenic gene expression program, glucagon stimulation tests
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were performed. However, loss of hepatocytic Creb did not change post-glucagon blood
glucose levels compared to controls with intact hepatic Creb (Figure 3.4d).

3.3.4

Loss of Creb does not improve nor aggravate fatty liver condition in insulinresistance mice
Previous studies reported opposite effect of Creb inhibition on fatty liver

condition. Hepatic lipid accumulation was significantly increased in mice expressing ACREB compared to controls (Herzig et al. 2003), while Creb-ASO treatment alleviated
fatty liver condition by lowering hepatic lipid levels and lipogenic gene expression levels
(Erion et al. 2009). To understand the role of Creb in the regulation of hepatic lipid
accumulation, fatty liver condition was evaluated via histology of high-fat diet fed
control and hepatocytic Creb mutant mice. H&E (Figure 3.5a, b) and Oil Red O (Figure
3.5c, d) staining of liver sections revealed no significant alterations in high-fat diet
induced fatty liver condition in hepatocytic Creb-null mice compared to controls.
Furthermore, hepatic triglyceride and cholesterol levels were comparable between the
two groups (Figure 3.5e, f). In addition, loss of Creb in hepatocytes did not change
circulating lipid levels and alanine transaminase (ALT) levels compared to controls
(Figure 3.6).
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3.3.5

Expression of gluconeogenic genes does not change in the absence of
hepatocytic Creb
Although there were no physiological changes in hepatocyte-specific Creb null

mice, I investigated the effect of hepatocytic Creb ablation at the transcriptional level.
To this end, I harvested livers after an overnight fast to ensure full activation of the
gluconeogenic gene expression program. Next, mRNA levels of key gluconeogenic genes
were measured, such as peroxisome proliferator-activated receptor gamma coactivator 1alpha (Pgc1α), glucose 6-phosphatase (G6pase), phosphoenolpyruvate carboxykinase
(Pepck), and fructose bisphosphatase (Fbpase), in regular chow fed (Figure 3.7a) or highfat diet fed mice (Figure 3.7b) via quantitative RT-PCR. In contrast to previous studies
that had reported an 80% decrease in expression levels in mice expressing a dominantnegative mutant version of CREB relative to controls (Herzig et al., Nature 2001), I did
not observe any significant changes in steady-state mRNA levels of these gluconeogenic
genes in hepatocyte-specific Creb null mice (Figure 3.7a and b). To assess effects of
Creb on entire hepatic transcriptome, expression profiling via microarray was performed
(Figure 3.7c). Only 21 genes were significantly differentially expressed in Creb-null liver
compared with controls, none of which are known to function in glucose metabolism
(Table 3.1). This strongly suggest other factors, including other CREB-family members
which can also bind to common CRE site, may bind promoters of CREB target genes and
induce gene expression in the absence of CREB. cAMP-responsive element modulator
(CREM), another member of CREB family of DNA binding proteins, can also mediate
transcriptional response to cAMP signaling, and there is some functional redundancy
between CREB and CREB (Hummler et al. 1994). To determine potential functional
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compensation by CREM in the absence of CREB, Crem mRNA levels were measured. In
the livers of hepatocyte specific Creb-null mice, there was a 2-fold increase in Crem
expression levels, suggesting the regulation of CREB target genes by CREM (Figure 3.8).

3.4 Discussion
CREB has been established as the master regulator of gluconeogenesis during
fasting. Multiple studies were performed to determine the role of CREB in the liver by
utilizing tissue specific dominant-negative (Herzig et al. 2001; Herzig et al. 2003) or
antisense nucleotide approaches (Erion et al. 2009). Both approaches resulted in
significant decreases in blood glucose levels, and reduced gluconeogenic gene expression
in the liver. These results suggested CREB as a potential therapeutic target to improve
insulin sensitivity in type 2 diabetes patients. However the two approaches reported
divergent effects on hepatic triacylglycerol metabolism, strongly suggestive of nonspecific effects in one or both models. The two reports also differed on the proposed
mediators of hepatic CREB function. Thus, Herzig and colleagues reported that CREB
regulated hepatic lipid metabolism via peroxisome proliferator-activated receptor gamma
(PPARγ) (Herzig et al. 2003), while ASO treatment had no effect on PPARγ expression
levels (Erion et al. 2009). In addition, these studies neither directly nor specifically
addressed the role of hepatic CREB due to inherent limitations of the methodologies
employed. In both studies, CREB activity was suppressed in other tissues as well as the
liver. In the A-CREB study, expression of CREB was under the control of
cytomegalovirus (CMV) promoter (Herzig et al. 2001; Herzig et al. 2003), hence no
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tissue specificity could be achieved. Similarly, Creb-ASO lead to decrease in Creb
mRNA levels in both the liver and adipose tissue (Erion et al. 2009). Multiple organs in
the body control glucose metabolism, and alterations in any of its players can lead to the
disruption of regulation. For instance, there are suggestions that CREB in the brain might
be involved in regulation of appetite and food intake (Altarejos et al. 2008; Yadav et al.
2011; Ren et al. 2013). Therefore it is possible that the blood glucose lowering effect by
A-CREB or Creb-ASO were due to suppression of CREB in combination of tissues.
Furthermore, there are well documented off-target effects associated with dominantnegative CREB mutant proteins (Ahn et al. 1998), while the ASO approach lead to
decreased Creb mRNA levels in adipose tissue as well as in the liver (Erion et al. 2009).
In addition, it has been shown that ASO can have biological effects that are not solely
resulting in specific degradation of their target mRNAs (Woolf et al. 1992; Fisher et al.
2002).
To investigate the requirement for CREB in liver metabolism, I utilized the CreloxP system for conditional ablation of Creb in the adult hepatocytes. In my model, I was
able to confirm complete loss of CREB protein in every hepatocyte post AAV-Cre
injection, while expression of CREB in non-hepatocytes was maintained. In contrast to
previous studies suggesting improved insulin sensitivity through inhibition of CREB
activity via dominant-negative or ASO approach, deletion of hepatocytic Creb had no
effect on glucose homeostasis and insulin sensitivity. In addition, expression levels of key
gluconeogenic genes, such as Pgc-1α, G6pase, Pepck and FBPase, in Creb-deficient
liver were comparable to those of control mice, in contrast to previous studies reporting a
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50-80% decrease in expression levels following A-CREB overexpression or ASO
treatment (Herzig et al. 2003; Erion et al. 2009). In addition, as shown by global
expression profiling, Creb ablation had insignificant effect on genes involved in hepatic
metabolism and function, indicating that other factors may bind and regulate CREB
targets in the absence of CREB. Furthermore, deletion of Creb did not improve insulin
sensitivity of mice that were fed a high-fat diet to mimic type 2 diabetic conditions. The
different outcome of CREB deficiency reported here is likely due to the specificity of my
model system relative to the dominant-negative and ASO approach, which inhibits CREB
in multiple organs including the liver, and may impact factors other than CREB. My
results suggest functional redundancy between proteins that bind to CREs as indicated by
the lack of change in expression levels of CREB target genes in the absence of
hepatocytic CREB. Partial redundancy among members of mammalian transcription
factor gene family has been reported previously (Hummler et al. 1994), and an increased
expression levels of Crem in the hepatocytic Creb-null livers suggests potential
functional compensation. Nevertheless, these findings put into question the current status
of CREB as the master regulator of gluconeogenesis and the suitability of specific CREB
inhibitors as anti-diabetic drugs.
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Figure 3.1: Design of CrebloxP allele
loxP sites (white triangles) were positioned to flank the critical exon 11 of the Creb gene.
Mice harboring the Creb loxP allele were injected with AAV-Cre or AAV-GFP (control).
In hepatocytes, which are infected by AAV-Cre, removal of exon 11 produces a null
allele.
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Figure 3.2: Conditional gene ablation of Creb in hepatocytes
(a) Quantitative RT-PCR to measure Creb mRNA levels in the liver of Creb L/L mice
injected with control virus (AAV-GFP; black bar) or AAV-Cre (white bar). Transcription
levels in Creb L/L; AAV-GFP mice were set to 1. N  =  5 for each group. Values are
presented as average ± SE. *p  <  0.005. (b) Western blot analysis of whole-cell liver
lysates taken from livers of Creb L/L mice injected with AAV-GFP or AAV-Cre as
indicated. HNF4α was used as loading control. (c and d) Liver sections from mice of
indicated genotypes were stained with antibody against CREB (red) and HNF4α (green).
Only HNF4α− non-parenchymal cells maintain CREB expression (yellow arrowheads) in
Creb L/L; AAV-Cre livers. (e) Percentage of CREB+ hepatocytes (HNF4α+ cells) in
control (AAV-GFP injected; black bar) or mutant (AAV-Cre injected; white bar) liver.
n  =  3 for each group. *p  <  0.005.
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Figure 3.3: Mice lacking Creb in hepatocytes maintain normal glucose homeostasis
(a) Blood glucose levels of control (Creb L/L; AAV-GFP) and hepatocyte-specific Creb
mutant mice (Creb L/L; AAV-Cre) after 24 h fasting (0 time point) and during re-feeding
at the times indicated. N  =  5–6 for each group. (b) Blood glucose levels and (c) insulin
levels of control and Creb-deficient mice after overnight fasting (0 min) and following
injection of a glucose bolus (2 g/kg body weight) at the times indicated. N  =  5-6 for each
group. (d) Blood glucose levels of control and Creb-deficient mice after 3 h fasting (0
min) and following an insulin injection at the times indicated. n  =  5 for each group. (e)
Blood glucose levels of control and Creb-deficient mice during the course of 72 h fast.
N  =  4 for each group. Black squares, Creb L/L; AAV-GFP. White diamonds, Creb L/L;
AAV-Cre.
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Figure 3.4: Deletion of hepatocytic Creb does not improve glucose homeostasis of
high-fat diet fed mice
(a) Blood glucose levels of high-fat diet fed control (Creb L/L; AAV-GFP) and
hepatocyte-specific Creb-null mice (Creb L/L; AAV-Cre) after 24 h fasting (0 time point)
and during re-feeding at the times indicated. N  =  9 for each group. (b) Blood glucose
levels of high-fat diet fed control and Creb-deficient mice after overnight fast (0 time
point) and following injection of a glucose bolus (1.5 g/kg body weight) at the times
indicated. N  =  15 for each group. (c) Blood glucose levels of high-fat diet fed control and
Creb mutant mice after 3 h fasting (0 time point) and following an insulin injection at the
times indicated. N  =  6–7 for each group. (d) Blood glucose levels of high-fat diet control
and Creb-deficient mice after 3 h fasting (0 time point) and following a glucagon
injection at the times indicated. n  =  5 for each group. Black squares, Creb L/L; AAV-GFP.
White diamonds, Creb L/L; AAV-Cre.
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Figure 3.5: Deletion of hepatocytic Creb does not improve fatty liver of high-fat diet
fed mice
(a and b) H&E staining of liver sections from mice of indicated genotypes (c and d) Liver
sections from mice of indicated genotypes were stained with Oil Red O visualization of
neutral triglycerides and lipids. Quantitative measurement of triglyceride (e) and
Cholesterol (f) levels in high-fat diet fed control (Creb L/L; AAV-GFP; black bar) or
mutant (Creb L/L; AAV-Cre; white bar) livers. Values are presented as average ± SE.
n=11 for each group.

48	
  

	
  

Figure 3.6: Loss of CREB in hepatocytes does not change plasma lipid profiles
To determine lipid profiles in circulations, plasma triglyceride (a), non-esterified fatty
acids (NEFA; b), phospholipid (c), high-density lipoprotein (HDL; d), cholesterol (e),
and non-HDL-cholesterol (f) levels were measured in high-fat diet fed control (AAVGFP injected; black bar) or mutant (AAV-Cre injected; white bar) mice. In addition,
Plasma alanine transaminase (ALT; g) levels were measured to detect liver injury. Values
are presented as average ± SE. n=7 for each group.
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Figure 3.7: Loss of CREB in hepatocytes does not change gluconeogenic gene
expression
(a) Quantitative RT-PCR to measure mRNA levels of Pgc1α, G6pase, Pepck and Fbpase
in the liver of control and liver-specific Creb mutant mice after an overnight fast. n  =  5–6
for each group. (b) Quantitative RT-PCR to measure relative mRNA levels of Pgc1α,
G6pase, Pepck and Fbpase in the liver of high-fat fed control and hepatocyte-specific
Creb-deficient mice after an overnight fast. n  =  5–6 for each group. Transcription levels
of control mice were set to 1. Values are presented as average ± SE. Black bar, Creb L/L;
AAV-GFP. White bar, Creb L/L; AAV-Cre. (c) MA-plot of Creb L/L; AAV-GFP liver
RNA vs. Creb L/L; AAV-Cre liver RNA from regular chow diet fed mice after an
overnight fast. The M-axis is the log2 fold-change between the two groups, while the Aaxis denotes the log2 average intensity in the two groups. Each point represents a gene
(grey), and significantly differentially expressed genes (10% false discovery rate, >1.5fold change) are marked in black. The dashed line indicates median M value for all
points.
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Figure 3.8: Crem expression levels were increased by 2-fold in the livers of mice
lacking hepatocytic Creb
Quantitative RT-PCR to measure mRNA levels of Crem in iWAT and BAT of control
and adipocyte-specific Creb-null mice. Black bar, Creb L/L; AAV-GFP. White bar, Creb
L/L
; AAV-Cre. Transcription levels in CrebL/L mice were set to 1. Values are presented as
average ± SE. *p < 0.05. n = 5–6 for each group.
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Gene Name

Description

Fold
Change

Mup20

major urinary protein 20

2.136

Moxd1

monooxygenase, DBH-like 1

1.915

NAP112258-1

major urinary protein, pseudogene 10

1.846

Cyp2c55

cytochrome P450, family 2, subfamily c, polypeptide 55

1.705

A_55_P2144090

major urinary protein, pseudogene 3

1.69

Tceal8

transcription elongation factor A (SII)-like 8

-1.592

Olfr1229

olfactory receptor 1229

-1.592

1700013B16Rik

RIKEN cDNA 1700013B16 gene

-1.595

Clpx

caseinolytic peptidase X (E.coli)

-1.631

Gpr137b

G protein-coupled receptor 137B

-1.88

Ttc37

tetratricopeptide repeat domain 37

-2.141

Mfsd6

major facilitator superfamily domain containing 6

-2.342

E130012A19Rik

RIKEN cDNA E130012A19 gene

-2.41

Neat1

nuclear paraspeckle assembly transcript 1 (non-protein -2.564
coding)

Camk2n2

calcium/calmodulin-dependent protein kinase II inhibitor 2

-2.674

Tmem215

transmembrane protein 215

-2.703

Kif4b

kinesin family member 4B

-3.165

Cntn4

contactin 4

-3.322

Krtap5-5

keratin associated protein 5-5

-5.348

2310065F04Rik

RIKEN cDNA 2310065F04 gene

-7.042

Ren1

renin 1 structural

-15.152

Table 3.1: Significantly differentially expressed genes in hepatocyte specific Crebnull liver
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CHAPTER 4: Adipocytic CREB Regulates Fasting-Induced
Lipolysis but Has No Non-Redundant Function in
Thermogenesis
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4.1 Abstract
Lipolysis and thermogenesis are regulated by catecholamines signaling via βadrenergic receptors in adipose tissue. Previous studies suggested a role for the cAMPresponsive transcription factor cAMP-responsive element binding protein (CREB) in
adipocyte function, but this hypothesis was never functionally confirmed by an adiposespecific ablation of Creb in vivo. Here, I test directly the requirement for adipocyte
CREB for lipolysis and thermogenesis using the Cre-loxP system for adipocyte-specific
ablation of Creb in mice. Loss of adipocytic Creb lead to a moderate decrease in fastinginduced lipolysis in adipose tissue. Strikingly, the adipocytic transcriptome was not
globally affected by ablation of Creb. In addition, cold temperature and cAMP signalinginduced thermogenesis and white-to-beige adipocyte conversion were not changed in
adipocyte specific Creb-null mice compared to controls. In conclusion, my data indicate
that CREB has no non-redundant functions in thermogenesis, but contributes to the
regulation of fasting-induced lipolysis. The underlying mechanism of reduced fastinginduced lipolysis in adipocytic CREB-deficient mice will need to be explored further.
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4.2 Introduction
Adipose tissue is an active metabolic organ, in which excess energy is stored for
use in times of food deprivation in the form of lipids. In addition, adipose tissue also
provides protection and insulation for internal organs, generates body heat, and
communicates with other organs via adipose-derived hormones. The two types of
adipocytes that comprise the majority of adipose tissue are white adipocytes and brown
adipocytes. Unilocular white adipocytes store energy in the form of large single lipid
droplets in their cytoplasm. Unlike white adipocytes, multilocular brown adipocytes carry
fat in multiple small lipid droplets, and also contain numerous mitochondria, which give
brown fat its dark color. The main function of brown adipocytes is thermogenesis in
response to cold exposure. (Rothwell and Stock 1979; Rothwell et al. 1982). Brown
adipocytes express uncoupling protein-1 (UCP1) in the inner membranes of
mitochondria, which assist heat production by uncoupling oxidative phosphorylation
from electron transport. Prolonged exposure to low temperature or catecholamine
signaling results in the transformation of subpopulations of white adipocytes into beige
adipocytes that expresses UCP1 (Young et al. 1984; Cousin et al. 1992; Petrovic et al.
2010).
There are multiple adipose depots in the body. The major fat depots are
abdominal subcutaneous white adipose tissue, visceral white adipose tissue, and
subclavicular/subscapular brown adipose tissue. (Frühbeck 2008; Bjorndal et al. 2011;
Cinti 2012). Both white adipose tissue (WAT) and brown adipose tissue (BAT) are
innervated by sympathetic nerve endings (Cottle and Cottle 1970; Bowers et al. 2004;
Bartness et al. 2010). Lipolysis and thermogenesis are regulated by catecholamine
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signaling via β-adrenergic receptors (Landsberg et al. 1984; Carpéné et al. 1998). Binding
of the catecholamine norepinephrine to β3-adrenergic receptors on brown and white
adipocytes leads to increased cytoplasmic cAMP levels, which activate protein kinase A
(PKA). PKA phosphorylates hormone-sensitive lipase (HSL), and activated HSL
hydrolyzes lipid triacylglycerols in lipid droplets, releasing glycerol and fatty acids. In
brown adipocytes, released fatty acids activate UCP1, in addition to acting as substrates
for oxidative phosphorylation.
Although all adipose depots play a role in buffering energy imbalance, metabolic
rates can vary among the depots. For example, visceral white fat is more metabolically
active than subcutaneous white fat, contributing more to circulating free fatty acid levels
(Wajchenberg 2000; Hajer et al. 2008). Due to the difference in lipolytic rates, visceral
fat contributes more in development of metabolic syndrome and type 2 diabetes mellitus
(T2DM) relative to the other depots (Bjorndal et al. 2011). Furthermore, white adipocytes
in inguinal subcutaneous WAT are more susceptible to beige transformation than those in
epididymal WAT, even though all white fat depots express Ucp1 upon cold exposure or
catecholamine treatment. (Himms-Hagen et al. 2000; Barbatelli et al. 2010; Vitali et al.
2012; Wu et al. 2012; Harms and Seale 2013).
Recently, BAT has received increased attention recently due to its implications as
a potential target for the treatment of obesity (Lockie et al. 2013; Mund and Frishman
2013; Chechi et al. 2014). In rodents, ablation of BAT or UCP1 leads to obesity due to
loss of diet-induced thermogenesis (Lowell et al. 1993; Feldmann et al. 2009). Similarly,
chronic treatment with a β3-adrenergic receptor-specific agonist reverses obesity and
insulin-resistance in rodents (Ghorbani et al. 1997; Ghorbani and Himms-Hagen 1997;
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Liu et al. 1998). These data suggest that heat production from BAT is a critical regulator
of whole body energy metabolism. In humans, presence of BAT in adults has only been
recognized recently (Hany et al. 2002; Yeung et al. 2003). Some studies have indicated
an inverse correlation between body mass index and BAT activity (Cypess et al. 2009;
Saito et al. 2009; van Marken Lichtenbelt et al. 2009). Therefore, BAT activity can
potentially contribute to energy expenditure in adult humans. Furthermore, molecular
characteristics of human brown adipocytes are similar to that of murine beige adipocytes
rather than brown adipocytes (Wu et al. 2006). Thus, stimulants that induce ‘browning’
of white adipose tissue may be useful in treating obesity and diabetes in humans.
cAMP response element-binding protein (CREB) is a transcription factor that
binds to cAMP response elements (CREs) in cis-regulatory regions, and mediates cAMP
effects on transcriptional regulation. In adipocytes, β3- adrenergic signaling can activate
CREB (Chaudhry and Granneman 1999; Thonberg et al. 2002). In a previous study,
obese mice expressing a dominant-negative CREB specifically in brown and white
adipocytes displayed improved insulin sensitivity, and were protected from adipose tissue
inflammation (Qi et al. 2009). In addition, CREB-regulated transcription coactivator 3
(CRTC3) was shown to promote obesity by attenuating β-adrenergic receptor signaling in
adipose tissue (Song et al. 2010). The proximal promoter region of the mouse Ucp1 gene
contains CRE half-sites along with other cis-regulatory elements (Kozak et al. 1994; Rim
and Kozak 2002), suggesting possible direct regulation of its expression by CREB. In
fact, cold-stimulated Ucp1 levels in beige adipocytes were higher in the A/J strain of
mice compared to that of the obesity-prone C57BL/6J strain, and correlated with higher
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activation of CREB (Xue et al. 2005). Furthermore, adipocytic CREB has been shown to
regulate cAMP-induced expression of peroxisome proliferator-activated receptor- γ
coactivator-1α (Pgc1α) (Karamanlidis et al. 2007; Karamitri et al. 2009), which enhances
Ucp1 expression during cold-induced thermogenesis. Therefore, I investigated the role of
CREB in adipose tissue, taking advantage of the Cre-LoxP cell type specific gene
ablation approach. I hypothesized that loss of CREB in adipose tissue would lead to a
decrease in lipolysis and thermogenesis. In my study, loss of adipocytic CREB leads to a
moderate decrease in adipose tissue lipolysis. After subsequent evaluation of BAT
activation and β3-adrenergic receptor specific agonist-induced browning of white
adipocytes, I demonstrate that CREB is not required for the regulation of thermogenesis.

4.3 Results

4.3.1

Ablation of CREB in Adipose Tissue does not affect body composition and
adipocyte morphology
To assess adipocytic CREB function in vivo, I crossed homozygous CrebloxP mice

(Lee et al. 2014) with Adipoq-Cre mice, which expresses Cre recombinase in adipocytes
(Eguchi et al. 2011; Lee et al. 2013). Quantitative RT-PCR confirmed an ~80% decrease
in Creb mRNA levels in both inguinal WAT (iWAT) and interscapular BAT of
CrebloxP/loxP; Adipoq-Cre mice (Figure 4.1a). Effective reduction in CREB protein levels
in iWAT and BAT was confirmed by western blotting (Figure 4.1b).
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Body composition was determined using nuclear magnetic resonance (NMR), and
calculated as percentage lean and fat mass of total body weight for both the control and
adipocyte-specific CREB-null mice. Body weights were comparable between the two
groups, with similar lean to fat mass ratios, indicating that loss of adipocytic CREB did
not affect overall body composition (Figure 4.2). Furthermore, there were also no
significant difference in the histology of iWAT and BAT of adipocytic CREB-null mice
relative to controls (Figure 4.3).

4.3.2

Loss of CREB in adipose tissue decreases fasting plasma fatty acid levels
During fasting, glucagon and catecholamine induce lipolysis in adipose tissue to

release fatty acids and glycerol, which are utilized in peripheral tissues for energy
production. To investigate the role of CREB in lipolysis, I measured circulating lipid
levels in control and adipocyte-specific CREB-null mice during fasting and refeeding.
Interestingly, while plasma triacylglycerol levels and ketone body levels were unchanged,
fasting plasma non-esterified fatty acids (NEFA) levels were 40% lower in CrebloxP/loxP;
Adipoq-Cre mice compared to controls (Figure 4.4a, c, and d), indicating defects in
fasting-induced lipolysis.
Adiponectin is an adipose tissue secreted hormone involved in the regulation of
glucose and fatty acid metabolism. In adipose tissue, adiponectin facilitates lipid uptake
and inhibits lipolysis (Kim et al. 2007; Qiao et al. 2011; Wedellová et al. 2011). In a
previous study, inhibition of adipocytic CREB using a dominant-negative approach led to
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an increase in circulating adiponectin levels (Qi et al. 2009). I measured circulating
adiponectin levels to determine if loss of adipocytic CREB had any effect on adiponectin
secretion in my model. Plasma adiponectin levels of adipocyte-specific CREB-null mice
were comparable to those of control mice (Figure 4.4b).
To assess the involvement of CREB in the adipocyte transcriptome, I performed
expression profiling via microarray in epididymal WAT isolated from both adipocytic
Creb-null mice and controls that were fasted overnight. Surprisingly, loss of CREB had
no effect on WAT gene expression and only a single gene, TAF-6-like RNA Polymerase
II, p300/CBP-associated factor (PCAF)-associated factor (Taf6l), was found to be
differentially expressed between CrebloxP/loxP and CrebloxP/loxP; Adipoq-Cre (Table 4.1).
Despite a 10-fold increase in expression levels, currently there is no known function for
taf6l in lipid metabolism. Thus, the underlying mechanism of reduced fasting-induced
lipolysis in adipocytic CREB-deficient mice it is still unclear, and further studies need to
be performed to address this issue.

4.3.3

Ablation of adipocytic Creb does not affect BAT activity
Although loss of Creb in adipose tissue did not affect the morphology of BAT, I

nevertheless investigated if Creb deficiency affected thermogenesis. To evaluate coldinduced thermogenesis, mice were kept at 4°C for 3 hours, and the core temperature was
measured every 30 minutes. There were no appreciable differences in the changes of core
temperature between CrebloxP/loxP and CrebloxP/loxP; Adipoq-Cre mice (Figure 4.5).
Because mice are able to maintain their core temperature via shivering as well as by
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thermogenesis, I wanted to further determine and confirm the degree of BAT activation
in adipocytic Creb-null mice.
To remove any shivering effects, I utilized pharmacological reagents to induce
BAT activation. In vivo, BAT thermogenesis is activated by norepinephrine from the
sympathetic nervous system (Landsberg et al. 1984). Mice were anesthetized and kept at
30°C, within the mouse thermoneutrality zone, during the course of the experiment to
exclude shivering-induced thermogenesis. Norepinephrine-induced heat production was
calculated by measuring CO2 production and O2 consumption. At the basal state, heat
production was not significantly different between control mice and adipocyte-specific
CREB mutants (Figure 4.6). Treatment with subcutaneous injection of norepinephrine
increased body heat production by 5-fold in both control and mutant animals, and both
the CO2 production and the O2 consumption were comparable between the two groups
(Figure 4.6). These results indicate that loss of Creb has no effect on norepinephrineinduced thermogenesis.
In brown adipocytes, the effect of norepinephrine is carried out by β3-adrenergic
receptors coupled to the cAMP-signaling pathway (Cannon et al. 1996). However, it is
important to note that norepinephrine also targets the liver and skeletal muscle as well as
adipose tissue. Since β3-adrenergic receptors are mainly present in adipose tissue, I
decided to repeat the above experiment using the highly selective β3-adrenergic receptor
agonist CL-316,243, to eliminate any potential influence of other tissues on heat
production. CL-316,243 was previously demonstrated to increase energy expenditure by
activating thermogenesis in BAT (Grujic et al. 1997). Overall, the effects of CL-316,243
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on CO2 production and O2 consumption were similar to those of norepinephrine, and loss
of CREB had no effect on CL 316,243-induced heat production (Figure 4.7). This
suggests CREB is not required for β3-adrenergic receptor-mediated thermogenesis by
BAT.

4.3.4

CREB is not required for CL-316,243-induced thermogenic gene expression.
Prolonged exposures to cold temperatures or treatment with β3-adrenergic

receptor agonists, promotes the transformation of subpopulations of white adipocytes into
beige adipocytes that express Ucp1 (Young et al. 1984; Cousin et al. 1992; Petrovic et al.
2010). Ucp1 contains CRE half-sites in its proximal promoter region (Kozak et al. 1994;
Rim and Kozak 2002), and CREB can potentially regulate its expression during white-tobeige transformation at the transcriptional level. To further test the role of CREB in this
process, both adipocytic CREB-null and control mice were kept within thermoneutrality
and treated with CL-316,243 for 3 days. BAT and iWAT were harvested, and quantitative
PR-PCR was performed to determine the expression levels of BAT identity genes and
thermogenic genes. As expected, CL-316,243 treatment increased expression of
thermogenic genes such as Ucp1, Pgc-1α, and type II iodothyronine deiodinase (Dio2) in
BAT (Figure 4.8a). Loss of CREB did not have any effect on expression of BAT identity
genes (Figure 4.8b). In iWAT, CL-316,243 treatment increased expression of Ucp1,
indicating the presence of beige adipocytes (Figure 4.9a). Absence of CREB had no
significant impact on CL-316,243-induced expression of thermogenic genes in iWAT
(Figure 4.9a). As reported previously, expression levels of Cidea were increased in
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iWAT after CL-316,243 (Figure 4.9b). However, the expression levels of BAT identity
genes were similar between control and CREB-null cells (Figure 4.9b). These results
indicate that both the transcriptional regulation of thermogenic genes by the cAMP
signaling pathway and the browning of white adipocytes do not require CREB.

4.4 Discussion
Previous studies suggested a role for CREB in adipocyte function, but this
hypothesis was never functionally confirmed by an adipose-specific ablation of Creb in
vivo. Inhibition of CREB reduced inflammations in adipose tissue and increased secretion
of adiponectin in mice expressing adipocytic A-CREB (Qi et al. 2009). However, there
are well documented off-target effects associated with dominant-negative CREB mutant
proteins (Ahn et al. 1998). Thus it is possible that the inhibition of combinations of
proteins by dimerization with A-CREBs lead to the observed phenotype in the study
above.

Furthermore, a role for CREB in the regulation of thermogenesis and

development of beige adipocytes, had been suggested based on enhanced CREB
expression and activation in brown adipocytes upon rise in intracellular cAMP levels
(Chaudhry and Granneman 1999; Thonberg et al. 2002), and CREB’s observed ability to
regulate the expression of Pgc1α and Ucp1 (Kozak et al. 1994; Nedergaard et al. 2001;
Rim and Kozak 2002). However, none of above studies investigated the requirement of
CREB in thermogenesis.
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To directly evaluate the requirement of CREB in lipolysis and thermogenesis, I
utilized the Cre-loxP system for adipocyte specific ablation of Creb in mice. Loss of
adipocytic CREB did not affect body weight or composition. BAT and iWAT of adipose
tissue-specific CREB mutant had normal histology compared to controls. Interestingly,
fasting-induced lipolysis was reduced in adipocytic CREB-null mice, but there were no
alterations in circulating adiponectin levels. Expression analysis of global RNA levels in
white adipose tissue did not reveal any potential mechanism underling the suppression of
lipolysis in mice lacking adipocytic CREB. This might be explained in part by the fact
that only a subpopulation of adipocytes in white adipose tissue undergoes lipolysis upon
catecholamine signaling and that this changes in gene expression in a subset of
adipocytes are masked by the bulk of unresponsive cells. To address this issue, future
experiments will examine the effect of loss of CREB on lipolysis and lipolytic gene
expression in vitro using primary adipocytes.
In regards to CREB’s role in thermogenesis, CrebloxP/loxP; Adipoq-Cre mice had
similar cold tolerance as the control mice. BAT activation was further tested by treatment
with norepinephrine and β3-adrenergic agonist CL-316,243. Despite the suggestions from
previous studies, loss of CREB had no effect on thermogenesis. Furthermore, expression
levels of Ucp1 and Pgc1α in adipocytic CREB-null BAT and iWAT were comparable to
those of controls in both saline and CL-316,243 treated animals, suggesting proteins
besides CREB can also bind to cis-regulatory elements in thermogenic genes containing
CREs, and regulate their expression. Partial functional redundancy exists between the
CREB/AFT family members that share dimerization domain and kinase-inducible
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domain with CREB (Hummler et al. 1994), and they may be able to dimerize and recruit
other transcription factors to promoters of target genes in the absence of CREB. This
study thoroughly examined the role of CREB in thermogenesis at both the physiological
and molecular levels, and I conclude that there are no non-redundant functions of CREB
in the cAMP-mediated activation of thermogenesis and the white-to-beige adipocyte
transformation, while it regulates fasting-induced lipolysis through an as of yet unknown
mechanism.
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Figure 4.1: Creb ablation in adipocytes
(a) Quantitative RT-PCR to determine Creb mRNA levels in iWAT and BAT.
Transcription levels in CrebL/L mice in each tissue were set to 1. Values are presented as
the average ± SE. *p < 0.005. n = 7–8 for each group. (b) Western blot analysis of wholecell lysates confirms loss of CREB in mutant CrebL/L; Adipoq-Cre mice in both iWAT
and BAT of control and mutant mice as indicated. Cyclophilin B was used as a loading
control.
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Figure 4.2: Loss of CREB does not affect body composition
Body weight and nuclear magnetic resonance (NMR) analysis to determine the percent
lean mass and percent fat mass of control (CrebL/L) and mutant (CrebL/L; Adipoq-Cre)
mice. Values are presented as the average ± SE. n=7–8 in each group.
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Figure 4.3: Creb-null iWAT and BAT displayed normal adipocyte morphology
H&E staining of iWAT and BAT isolated from both control (CrebL/L) and mutant
(CrebL/L; Adipoq-Cre) mice.
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Figure 4.4: Reduction of fasting plasma non-esterified fatty acids (NEFA) levels in
adipocytic CREB-null mice
Circulating NEFA (a), adiponectin (b), triacylglyceride (c), and β-hydroxybutyrate (d)
levels were measured. Fasted plasma was collected after 16hr fasting, and refed plasma
was collected after 2hr refeeding. Values are presented as average ± SE. n=17–18 in each
group.
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Figure 4.5: Response to cold exposure was not affected by the loss of adipocytic
CREB
Core temperature measurements of Crebloxp/loxp and Crebloxp/loxp; Adipoq-Cre mice during
3 hour exposure to 4°C. Values are presented as the average ± SE. n=4-5 for each group.
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Figure 4.6: Adipocytic CREB-null mice exhibited similar norepinephrine (NE)induced thermogenesis
O2 consumption and CO2 production were measured before and after NE injection. Heat
production was calculated via indirect calorimetry. Mice were kept under anesthesia and
at 30°C during the experiment. Values are presented as the average ± SE. n=3–4 for each
group.
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Figure 4.7: CL-316,243-induced thermogenesis of adipocyte specific CREB mutant
mice was similar to controls
CL-316,243 is a β3-adrenergic receptor agonist. O2 consumption and CO2 production was
measured before and after CL-316,243 injection. Heat production was calculated via
indirect calorimetry. Mice were kept under anesthesia and at 30°C during the experiment.
Values are presented as the average ± SE. n=4–7 for each group.
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Figure 4.8: CL-316,243-induced expression levels of thermogenic genes in BAT of
adipocytic CREB-null mice were similar to those of controls
(a) Quantitative RT-PCR to measure mRNA levels of Ucp1, Pgc1α, and Dio2 in the BAT
of control and adipocyte-specific adipocytic Creb mutant mice after 3-day injection with
saline or CL-316,243. n  =  9–12 for each group. (b) Quantitative RT-PCR to measure
relative mRNA levels of Prdm16, Pparα and Cidea in BAT of control and adipocytespecific Creb-deficient mice after saline or CL-316,243 treatment for 3 days.
Transcription levels of control mice were set to 1. Values are presented as the average ±
SE. n  =  9–12 for each group.
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Figure 4.9: Similar expression levels of thermogenic and BAT identity genes in
inguinal WAT (iWAT) of adipocytic Creb-null mice compared to controls
(a) Quantitative RT-PCR to measure mRNA levels of Ucp1, Pgc1α, and Dio2 in the
iWAT of control (CrebL/L) and adipocyte-specific Creb mutant (CrebL/L; Adipoq-Cre)
mice after 3-day injection with saline or CL-316,243. n  =  9–12 for each group. (b)
Quantitative RT-PCR to measure relative mRNA levels of Prdm16, Pparα and Cidea in
iWAT of control and adipocyte-specific Creb-deficient mice after saline or CL-316,243
treatment for 3 days. Transcription levels of control mice were set to 1. Values are
presented as the average ± SE. n  =  9–12 for each group.
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Gene Name

Description

Taf6l

TAF-6-like RNA Polymerase II, p300/CBP-associated
factor (PCAF)-associated factor

Fold
Change
10.79

Table 4.1: A Single gene was significantly differentially expressed in adipocyte
specific Creb-null eWAT
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CHAPTER 5: Thesis Summary and Future Directions
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5.1 Thesis Summary
In this thesis, I investigated of the role of the transcription factor CREB in the
function of the liver and adipose tissue. Initially, I evaluated the role of hepatic CREB in
glucose homeostasis and insulin sensitivity. Previous studies described CREB as the
central regulator of the gluconeogenesis in the liver (Herzig et al. 2001; Erion et al. 2009).
In those studies, inhibition of CREB activity reduced blood glucose levels and improved
whole-body insulin sensitivity in rodent models of diabetes and insulin resistance,
suggesting CREB as a potential therapeutic target to reduce hyperglycemia in T2DM
patients. However, those studies utilized approaches that did not specifically target
hepatocytic CREB. Therefore, I employed the Cre-loxP system to specifically determine
the role of CREB in the regulation of hepatic glucose metabolism in Chapter III.
Contrary to the previous understanding of CREB function, I report that glucose
homeostasis was unaffected in mice conditionally deficient for Creb in the hepatocyte
lineage (CrebL/L; AAV-Cre). In addition, loss of hepatocytic CREB did not improve
insulin sensitivity in mice fed a high fat diet. Indeed, gluconeogenic gene expression
levels in hepatocytic Creb mutants were comparable to those of controls. Therefore,
CREB has no non-redundant function in hepatic glucose metabolism. My data questions
previous understanding of CREB and its suggested role in regulation of gluconeogenesis,
and thus CREB is not a plausible therapeutic target to treat T2DM.
Secondly, I investigated the role of CREB in the regulation of lipolysis and
thermogenesis in adipose tissue. Previous reports suggested CREB as a mediator for
cAMP-effects on transcriptional regulation of lipogenic and thermogenic genes by
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directly binding to their cis-regulatory regions (Kozak et al. 1994; Rim and Kozak 2002;
Karamanlidis et al. 2007; Karamitri et al. 2009). However despite these suggestions, the
function of CREB in adipocytes had never been directly evaluated. To assess adipocytic
CREB function in vivo, I crossed homozygous CrebloxP mice (Lee et al. 2014) with
Adipoq-Cre mice, which expresses Cre recombinase in adipocytes (Eguchi et al. 2011;
Lee et al. 2013). In Chapter IV, I report data on the effect of Creb ablation in the
regulation of lipolysis and thermogenesis in adipose tissue. Body composition and
adipocyte morphology in adipocyte-specific Creb-null (CrebloxP/loxP; Adipoq-Cre) mice
were comparable to controls. Interestingly, fasting-induced lipolysis was moderately
decreased

in

adipocytic

Creb-null

mice.

Previous

studies

reported

reduced

catecholamine-induced lipolysis in obese subjects compared to non-obese subjects
(Jensen et al. 1989; Bougneres et al. 1997; Langin et al. 2005). My data suggest CREB is
required for fasting-induced lipolysis and dysfunction of CREB may contribute to the
development of obesity. However, the expression profiling of epididymal WAT using
microarray did not reveal potential CREB target genes that may affect lipolysis. Hence,
the underlying mechanism of reduced fasting-induced lipolysis in adipocytic CREBdeficient mice it is still unclear, and further studies need to be performed to address this
issue.
The understanding of CREB function in the liver and adipose tissue prior to this
work was largely based upon studies that utilized a dominant-negative inhibitor of CREB
(A-CREB) (Herzig et al. 2001; Herzig et al. 2003; Qi et al. 2009) or an antisense
oligonucleotide (ASO) approach (Erion et al. 2009). A key shortcoming of these studies
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is the lack of tissue specificity. CREB is a ubiquitously expressed transcription factor that
serves various functions in different tissues. Therefore, inhibition of CREB activity in
multiple metabolic tissues may lead to dysregulation of whole-body metabolism, making
it harder to determine the tissue-specific role of CREB in the regulation of metabolism.
Furthermore, the A-CREB dominant-negative model can inhibit other basic leucine
zipper proteins in addition to CREB. In the A-CREB protein, an acidic amphipathic
protein sequence replaces the CREB basic region connected to the N-terminus of the
dimerization domain, allowing it to form a heterodimer with endogenous CREB protein,
and prevents CREB binding to DNA (Ahn et al. 1998). Since the other members of the
CREB/ATF share a conserved dimerization domain with CREB (Hummler et al. 1994), it
is possible for A-CREB to inhibit these related proteins as well. Likewise, A-CREB may
also bind to other basic leucine zipper proteins such as CCAAT/enhancer-binding protein
beta (C/EBPβ), which dimerizes with CREB to bind CRE half-sites in Ucp1 gene
(Karamanlidis et al. 2007; Karamitri et al. 2009). The results of this thesis highlight the
importance of re-evaluating previously suggested drug targets for human disease, and
caution must to be taken when interpreting metabolic findings from mouse models with
ill-defined molecular manipulations.

5.2 Future Directions
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5.2.1

Functional redundancy among CREB, activating cAMP-responsive element
modulator (CREM) and transcription factor-1 (ATF1) in the regulation of
hepatic glucose metabolism
In Chapter III, I used conditional gene ablation to show that the transcription

factor Creb has no non-redundant function in hepatic glucose metabolism. In the absence
of hepatocytic CREB, there no changes in expression levels of proposed CREB target
genes, which I suggest was due to functional redundancy between members of the
CREB/ATF protein family. At least two additional members of the CREB/ATF family,
namely CREM and ATF1, can also mediate transcriptional responses to cAMP signaling
(Hurst and Jones 1987; Hai et al. 1988; Philippe and Missotten 1990; Hummler et al.
1994). These three CREB family members also share a conserved dimerization domain
and kinase-inducible domain, suggesting partial functional redundancy. Indeed, CREM
and ATF1 are capable of dimerizing with CREB as well as CREB, and all of which are
targeted by PKA for phosphorylation (Hummler et al. 1994).
In Chapter III, I observed a two-fold increase in Crem mRNA and protein levels
in the livers of CrebloxP/loxP;AAV-Cre mice. Therefore, absence of changes in blood
glucose levels and gluconeogenic gene expression in hepatocyte-specific Creb-null mice
is likely explained by functional compensation by CREM. Similar hypothesis can be
proposed with Aft1, if Atf1 expression levels in the livers of hepatocytic Creb-deficient
mice as well.
The

above

hypothesis

could

be

further

investigated

by

chromatin

immunoprecipitation sequencing (ChIP-Seq) to determine if CREM and ATF1 bind to
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CREB target genes in the absence of CREB. Comparison of these ChIP-Seq data to
existing genome-wide CREB-binding data (Everett et al. 2013) may also reveal specific
subclasses of CREB target genes are bound and regulated by CREM and ATF1. If CREM
and/or ATF1 bind to gluconeogenic genes in the absence of CREB, as I hypothesize, the
next step will be to generate mice with hepatocyte-specific ablation of Creb, Crem and
Atf1. First, mice carry loxP flanked alleles of Crem and Atf1will be generated and these
mice will be bred together with existing CrebloxP/loxP to generate CrebloxP/loxP; CremloxP/loxP
Atf1loxP/loxPmice. Hepatocyte-specific deletion of loxP-flanked alleles can be achieved by
injection of AAV-Cre, as I demonstrated in Chapter III. Evaluating glucose metabolism
and insulin resistance in these mice will complete the analysis of transcriptional
regulation of glucose homeostasis by the cAMP-responsive transcription factors in the
liver, and their impact on the regulation of blood glucose levels.
Genome-wide CREB-binding data revealed CREB binding at lipid metabolism
genes (Everett et al. 2013). However, previous studies reported contradicting effects of
CREB inhibition on the accumulation of lipid in the liver (Herzig et al. 2003; Erion et al.
2009). In Chapter III, I demonstrated that ablation of hepatocytic Creb alone does not
improve nor aggravate fatty liver condition in high-fat diet fed, insulin-resistance mice,
and this could be also due to potential functional compensation by CREM and ATF1.
Therefore, the evaluation of hepatic and circulating lipid levels in CrebloxP/loxP;
CremloxP/loxP; Atf1loxP/loxP; AAV-Cre mice is of particular importance, in order to
understand if the CREB family of DNA binding proteins plays a role in the regulation of
hepatic lipid metabolism.
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5.2.2

Mechanism underlying reduced fasting-induced lipogenesis in adipocytic
Creb-null mice
In Chapter IV, I demonstrated that CREB plays a role in the regulation of

lipolysis during fasting with adipocyte-specific deletion of Creb using Cre-loxP system.
However, transcriptome analysis of epididymal WAT by microarray expression profiling
did not reveal any potential mechanism underlying the suppression of lipolysis in mice
lacking adipocytic CREB. The absence of significantly differentially expressed genes in
the above analyses can be explained in part by the fact that only a subpopulation of
adipocytes in white adipose tissue undergoes lipolysis upon catecholamine signaling. It is
also possible that the microarray platform was not sensitive enough to detect small
changes in gene expression; this could overcome by the more sensitive RNA sequencingbased expression analysis.
To address these issues, primary preadipocytes isolated from mouse adipose
tissue will be differentiated in vitro to determine changes in lipolytic gene expression in
response to β-adrenergic signaling. Treating adipocytes with β-adrenergic agonist in
vitro will ensure induction of lipolysis in all cells. Mammalian preadipocyte
differentiation can be achieved in vitro with IDX cocktail, composed of insulin,
dexamethasone, and isobutylmethylxanthine (IBMX) (Green and Meuth 1974; Russell
and Ho 1976; Student et al. 1980). In preadipocytes, insulin signals through insulin
growth factor-1 (IGF1) receptor to activate the adipogenic cascade (Rosen and
MacDougald 2006). Dexamethasone treatment activates the glucocorticoid signaling
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pathway which regulates adipocyte differentiation (Chapman et al. 1985), and IBMX
increases intracellular cAMP levels by inhibiting soluble cyclic nucleotide (Elks and
Manganiello 1985).
I previously isolated primary preadipocytes from inguinal WAT (iWAT) of
CrebloxP/loxP; Adipoq-Cre mice, and differentiated them in vitro by addition of the IDX
cocktail. However, Creb was not deleted in differentiated adipocytes from CrebloxP/loxP;
Adipoq-Cre mice. Although Adipoq promoter should be active post-differentiation, it was
identified that Adipoq-Cre is not efficient in deleting loxP-flanked alleles in vitro.
Therefore, I am currently isolating primary preadipocytes from iWATs of CrebloxP/loxP
mice, and they will be differentiated into mature white adipocytes in the culture using
IDX cocktail. Ablation of Creb will be achieved by transfecting differentiated
CrebloxP/loxP primary preadipocytes with Cre-mRNA. CrebloxP/loxP cells transfected with
eGFP-mRNA will be used as controls. The cells will be treated with norepinephrine to
induce lipolysis, relative levels of lipolysis between Cre-mRNA and eGFP-mRNA
transfected adipocytes will be determined by measuring glycerol levels in collected
media. Cells will also be harvested for RNA, and quantitative RT-PCR will be performed
to determine and compare expression levels of lipolysis genes between Cre-mRNA and
eGFP-mRNA transfected-CrebL/L primary white adipocytes. If significantly differentially
expressed genes are identified, CREB binding at the promoters of these genes will be
determined by cross-referencing genome-wide CREB-binding data that I obtained
previously via chromatin-immunoprecipitation sequencing (ChIP-Seq) on white adipose
tissue.
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5.2.3

The role of adipocytic CREB in the development of insulin-resistance and
obesity
In humans, fat tissues from obese individuals are resistant to catecholamine-

induced lipolysis when compared to those of non-obese subjects (Jensen et al. 1989;
Bougneres et al. 1997; Langin et al. 2005). In Chapter IV, I demonstrated decreased
fasting-induced lipolysis in regular chow fed Creb-null mice. My results reinforce the
importance of understanding adipocytic CREB’s role in metabolic dysregulation, and
suggest CREB have therapeutic potential for treatment of obesity. The diet-induced
obesity model employed in Chapter III can be applied to CrebloxP/loxP; Adipoq-Cre mice to
study the function of Creb and lipolysis in the context of obesity and insulin-resistance.
Body composition, energy expenditure, and circulating lipid levels will be evaluated to
determine if ablation of Creb accelerates the development of obesity. In addition,
catecholamine-induced lipolysis can be evaluated in vitro using fat biopsies from
CrebloxP/loxP and CrebloxP/loxP; Adipoq-Cre mice. Should the role of CREB in the
development of obesity be confirmed in rodents, expression levels of Creb mRNA and
protein should be measured in fat biopsies from and obese and non-obese human subjects
to further validate CREB as a potential therapeutic target for obesity.

Although mice are commonly used in basic research to model human diseases,
many pharmacological agents that work well in mice turn out to be ineffective in humans.
Therefore, both similarities and differences between the mouse models of obesity and
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obesity in humans must be thoroughly investigated before any serious consideration of
mouse-model based targets can be used in human drug and therapeutic development.
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